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Supramolecular anticancer drug delivery systems
based on linear–dendritic copolymers
Homa Gheybia and Mohsen Adeli*a,b
Current cancer chemotherapy often suﬀers severe side-eﬀects of the administered cancer drugs on the
normal tissues. In addition, poor bioavailability, due to the low water solubility of the anticancer drugs,
limits their applications in chemotherapy. New delivery technologies could help overcome this challenge
by improving the water solubility and achieving the targeted delivery of the anticancer drugs. Linear–
dendritic hybrid nanomaterials, which combine the highly branched architectures and multifunctionality
of dendrimers with the processability of traditional linear–linear block copolymers, have been introduced
as ideal carriers in anticancer drug delivery applications. This review presents recent advances in the
investigational aspects of linear–dendritic copolymers to be applied as anticancer drug delivery vehicles.
We highlight the structures, synthesis of linear–dendritic block copolymers, interaction mechanisms
between linear–dendritic copolymers and anticancer drug molecules, and ﬁndings on their drug release
behavior and anticancer eﬃcacies in vitro and in vivo.
1. Introduction
Cancer is one of the leading causes of morbidity and accounts
for approximately 20% of all deaths world-wide (World Health
Organization). When a cell acquires enough mutations to
become cancerous, it will be replicated at a higher rate than
normal cells. After tumor mass formation, it is not possible for
the normal cells to compete with the cancerous ones for an
adequate supply of nutrients from the blood vessels.1–4 Clini-
cal surgery to remove a cancerous tumor is considered to be
the primary method for fighting cancer. However, surgery may
have undesirable side eﬀects, such as changing the growth
rate of the remaining cancer cells by triggering a faster meta-
static process. Following surgical resection, radiotherapy,
chemotherapy and immunotherapy are the most common
methods currently employed in the clinical management of
cancer.5,6 One of the major problems facing cancer chemother-
apy is the lack of mandatory selectivity of chemotherapeutic
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drugs to direct the cytotoxicity to tumor cells, leading to unde-
sirable side eﬀects.7,8 A promising approach to overcome this
problem is the application of nanomaterial based drug delivery
systems9 including inorganic or other solid nanoparticles
(gold,10,11 iron oxide,12,13 quantum dots14,15 and carbon
nanotubes16–18), polymeric micelles,19–21 dendrimers,22–24 and
liposomes.25,26 The advantages of such nanocarriers include
the ability to improve drug solubility and slow down the
metabolism of the drug, prolonging the circulation time,
tumor specific delivery, and higher accumulation in tumors
via the enhanced permeability and retention (EPR) eﬀect,
resulting in enhanced eﬃcacy and reducing side eﬀects.27–29
Use of nanomaterial based drug delivery systems for biomedi-
cal applications is one of the constituents of an emerging field
called nanomedicine, which has shown great promise for the
development of novel diagnostic, imaging, and therapeutic
agents for a variety of diseases, including cancer.30–35 Among
the nanomaterials, linear–dendritic hybrid materials are a
growing class of nanoscopic carriers, which combine the
highly branched architecture and multifunctionality of dendri-
mers with the processability of traditional linear–linear block
copolymers.36,37 The concept of the linear–dendritic block
copolymer was announced by the Fréchet group in the early
1990s for the first time; it included a polystyrene and a dendri-
tic poly(benzyl ether) block,38 and later on a PEG block and a
hydrophobic dendritic poly(benzyl ether) block.39 Because of
their unique self-assembly properties, linear–dendritic systems
have received increasing attention to use as a versatile platform
for drug delivery applications.40–42 Dendrimers oﬀer plenty of
advantages compared to other architectural forms of polymers
that have been used in drug-delivery systems. Unique charac-
teristics, such as highly branched globular architecture,
narrow polydispersity, nanometer size range, periphery
groups, physicochemical, and self-assembly properties make
dendrimers promising candidates in nanomedicine. The main
successes of dendrimers in nanomedicine resulted in their
appropriate, reproducible and optimized design parameters,
addressing the physicochemical limitations of classical drugs
(e.g. solubility, specificity, stability, biodistribution and thera-
peutic eﬃciency) and their ability to overcome biological
issues to reach the right target(s) (e.g. first-pass eﬀect, immune
clearance, cell penetration, oﬀ-target interactions, etc.).43–47
However, several drawbacks limit the transportation of small
guest molecules by perfect dendrimers. Perfect dendrimers
have a relatively rigid molecular structure with interior cavities,
which are not flexible, and have certain dimensions for accept-
ing guest molecules with a certain and defined size. For the
encapsulation and release of guest molecules from perfect den-
drimers, a protection and deprotection reaction series is necess-
ary. In contrast to the drawbacks of perfect dendrimers, linear–
dendritic copolymers have flexible interiors and can encapsulate
a variety of small guest molecules.48–51 Recently, it has been
shown that the transport capacity of some of linear–dendritic
copolymers is much more than that of perfect dendrimers.52,53
These advantages and interesting properties of linear–dendritic
polymers have stimulated investigation in this area.
Three strategies have been reported for the synthesis of
linear–dendritic copolymers54: (a) “coupling” method: coup-
ling of a dendron with a functionalized linear polymer;39 (b)
“chain-first” method: growth of a dendritic segment from the
terminal group of a linear polymer;55 (c) “dendron-first”
method: polymerization of a linear segment from the dendron
macroinitiator by controlled/“living” radical routes.56 These
synthetic strategies lead to low polydispersity and a great deal
of control over the molecular architecture of obtained linear–
dendritic copolymers.43,57–59
Gitsov has described detailed architectures of linear–den-
dritic hybrids in a valuable review.41 The building blocks of
the linear–dendritic copolymers can be positioned in several
distinct configurations, due to the presence of multiple
anchoring points in blocks. According to Gitsov’s classifi-
cation, the first general group contains a single monodendron
or dendrimer (D) and one (A), two (B), or multiple (C) linear
segments (L), attached at the “focal” point or at the peripheral
functional groups in the D fragments, Fig. 1.
The characteristic feature of the second group is the attach-
ment of two monodendrons to the extremities of a single
linear chain (E) or the incorporation of dendrimers into the
main linear chain (F), Fig. 2.
The third group unifies the structures, where mono-
dendrons are attached like “pendants” to a main linear chain
through short (G) or long spacers (H). When the linear chain
is “shrunk” (H), it is transformed into a star-like macro-
molecule, with the monodendrons anchored at the extremities
of the star arms (K), Fig. 3. A special case of K arises when the
core of the star is not a small multifunctional unit, but a
dendrimer.
A network constructed by dendrimers as the crosslinking
moieties and linear blocks as the interjunction fragments con-
stitutes a special case of “infinite” linear–dendritic copolymer,
Fig. 4.
Finally, the dendritic–linear–dendritic super dendrimer
shown in Fig. 5 represents the ultimate challenge in synthetic
organic and polymer chemistry.
Besides improving the water solubility of the hydrophobic
drugs, encapsulated by the hydrophobic interior of dendritic
segments,60–62 the reactive surface end groups of dendritic
Fig. 1 Linear–dendritic architectures; ﬁrst group: A, B and C. Structures
were ﬁrst published in ref. 41.
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blocks can be covalently attached to a variety of drugs and
therapeutic agents,63,64 targeting and imaging moieties,65–67
and bioactive molecules,68 to achieve targeting, imaging, and
therapeutic treatment of cancer. Several articles reviewed the
research activities generated on linear–dendritic hybrids from
Fig. 2 Linear–dendritic architectures; second group: E and
F. Structures were ﬁrst published in ref. 41.
Fig. 3 Linear–dendritic architectures; third group: G, H and
K. Structures were ﬁrst published in ref. 41.
Fig. 4 Linear–dendritic architectures; fourth group: M. Structures were
ﬁrst published in ref. 41.
Fig. 5 Linear–dendritic architectures; ﬁfth group: N. Structures were
ﬁrst published in ref. 41.
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diﬀerent points of view, such as discovery and synthetic strat-
egies, PEG–dendritic block copolymer applications, and DNA–
protein–dendritic biohybrids in nanobiotechnology.41,43,58,69,70
This review will focus on the potential of several (A), (E), and
(K) type linear–dendritic hybrids as nanosized carriers for anti-
cancer drug delivery systems. Specifically, we will describe the
synthesis methods of related linear–dendritic hybrids, loading/
conjugating of anticancer agents onto linear–dendritic car-
riers, and the associated in vitro and in vivo anticancer activity.
2. Strategies employed to load
anticancer drugs onto linear–dendritic
vehicles
Currently used cancer chemotherapeutics are often inadequate
to cure tumors because of the nonselectivity of these drugs,
resulting in dose-limiting side eﬀects. Strategies for reducing
the toxicity and side eﬀects without sacrificing eﬃcacy could
greatly improve treatment and quality of life for patients. Drug
delivery systems that are specific to tumor cells oﬀer both an
increased therapeutic index and a reduction in harmful side
eﬀects.71–73 Several attempts have been made to design linear–
dendritic copolymers as drug carriers. Drug molecules can be
transferred either as conjugated to the functional groups on
the dendritic structure or encapsulated by the hydrophobic
interior of the dendritic blocks. These two approaches have
been developed substantially, although each approach has its
own advantages and drawbacks.74–78
2.1. Linear–dendritic copolymers/drug conjugates produce
vehicles
By conjugating appropriate targeting moieties, drugs, and
imaging agents to linear–dendritic polymers, ‘smart’ drug-
delivery nanodevices can be developed that can target, deliver,
and monitor the progress of therapy.8,79 However, the conju-
gation generally requires multi-step organic reactions and the
covalent conjugation chemistry has to be optimized in order
for the drug molecules to be cleaved and released under
specific biological conditions.75
Drugs can be conjugated to linear–dendritic polymers,
either directly or via a linker/spacer including:
- acid-labile hydrazone linkages, which are stable at physio-
logical pH but readily cleaved under mildly acidic conditions,
e.g., inside endosomes and lysosomes;78
- ester linkages, which are hydrolyzed inside the cell by
esterase enzymes;8
- disulfide bonds, which are reduced by glutathione inside
the cytosol;80
- amide bond, but this bond is known to be very stable
chemically in a biological environment;81
- acid sensitive acetal bonds, which are stable at pH >7, can
be an interesting option. At mildly acidic pH, hydrolysis of the
acetals is expected to occur, generating hydroxyl groups.82
2.2. Linear–dendritic copolymers produce vehicles upon
encapsulation of drugs
In the physical encapsulated or complex form, the drugs can
be loaded onto the dendritic blocks by non-covalent inter-
actions such as van der Waals forces, hydrophobic inter-
actions, hydrogen bonding and electrostatic interactions
between oppositely charged fragments of drug molecule and
dendritic blocks.42,74,83 The latter approach is relatively simple;
however, in spite of significantly improving the water solubility
and bioavailability of the drugs, the in vivo stability of the
copolymer/drug complexes could be a challenging issue.75,84
3. Classiﬁcation based on the
loaded drug
The present review focus on the application of linear–dendritic
vehicles for the delivery of four anticancer drugs: paclitaxel,
doxorubicin, cisplatin, and camptothecin. The following
listing of drugs associated with carriers composed of linear–
dendritic copolymers provides an overview of the potential of
the linear–dendritic platform to serve as anticancer drug car-
riers (Fig. 6).
4. Paclitaxel
Paclitaxel (PTX), also known as Taxol (trade mark of Bristol–
Myers–Squibb), is one of the most eﬀective anticancer agents
against a wide spectrum of cancers including ovarian, breast,
and colon cancer. It exerts its antitumor eﬀect by binding to
microtubules and interfering with the normal growth of micro-
tubules during cell division, which especially aﬀects fast
growing cancer cells.61,85–89 However, systemically adminis-
tered PTX causes serious side eﬀects, such as neutropenia and
peripheral sensory neuropathy. On the other hand, to over-
come its limited solubility in water, paclitaxel (Taxol) is formu-
lated in an oily solution of Cremophor EL (polyethoxylated
castor oil) and absolute ethanol (1 : 1 v/v). This is known to
Fig. 6 Structures of (a) paclitaxel, (b) doxorubicin, (c) cis-platin, and (d)
camptothecin.
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create such eﬀects as anaphylaxis and other severe hyper-
sensitivity reactions attributable to Cremophor EL and
ethanol.85,86,90
4.1. Paclitaxel-encapsulated linear–dendritic block
copolymers
4.1.1. Physicochemical properties. In an attempt to over-
come the mentioned limitations, paclitaxel has been encapsu-
lated into micelle-based formulations. An interesting study has
reported a micellar linear–dendritic block copolymer com-
posed of polyethylene glycol (PEG, Mw = 5 KDa) and third gene-
ration polylysine terminated with 8 units of cholic acid (CA),
named PEG5K–CA8 telodendrimer (Fig. 7), for delivery of PTX
in the treatment of nude mice bearing ovarian cancer xeno-
grafts (Compound 1).84
Physical entrapment of paclitaxel in linear–dendritic
micelles has been carried out utilizing the hydrophobic inter-
actions between PTX and the dendritic cholic acid cluster,
resulting in high loading capacity (7.3 mg PTX mL−1) through
the evaporation method. The particle size of PEG5k–CA8 nano-
particles loaded with PTX was 56 nm, as measured by the
dynamic light scattering (DLS) method. Cryo-TEM images
showed that the particles were spherical in situ, and the sizes
were 50–60 nm, which was consistent with the results obtained
by DLS. PTX–PEG5k–CA8 NPs have also been found to be very
stable at 4 °C, showing no significant changes in average par-
ticle size over 6 months. On the other hand, Abraxane® (the
FDA-approved Albumin nanoparticle-bound Paclitaxel), was
unstable and started to form larger aggregates and precipitate
4 days after dissolving the white powder of Abraxane with
saline. The obtained PTX–PEG5k–CA8 NPs exhibited sustained
drug release into surrounding the PBS, rapid release of 20% of
the drug in the first 2 h, cumulative release of 35% of the drug
by 12 h, and a slow linear release of 75% of the drug by
156 h.84 In order to better define the relationship between the
structures of the PEGmk–CAn telodendrimers and their physico-
chemical properties for drug delivery, this group prepared a
series of stable micelle systems with tuneable particle sizes by
varying the PEG chain length and the number of cholic acids
in the dendritic core.90 Other natural lipophilic molecules
such as cholesterol formate (CF), lithocholic acid (LA) (both
with planar steroid scaﬀold), and heptadecanoic acid (HA)
(linear fatty acid) have also been substituted for cholic acid in
the PEG5k–CA8 linear–dendritic structure). The resulting
micelles, with low critical micelle concentrations (CMC) at
approximately 1 μM, tended to form precipitate in aqueous
solution, and their PTX loading capacities were rather low,90
indicating the essential role of facial amphiphilic cholic acid
for stabilizing telodendrimer micelles. Also by varying the PEG
chain length and the number of cholic acids in the dendritic
core, it has been determined that larger numbers of cholic
acids lead to low CMC, larger micelles with a heterogeneous
size distribution, and significant precipitation after PTX
loading. PEG5k–CA8 with a medium particle size of 61 nm and
the highest PTX loading capacity (7.3 mg PTX loaded in 20 mg
PEG5k–CA8 mL
−1, 36.5% (w/w) of drug/polymer ratio) has been
found to be the optimized structure for carrying the drug.90
The stability of the PTX-loaded PEG5k–CA8 micelles was fol-
lowed by the DLS particle sizer. The particle size of these PTX-
loaded micelles in aqueous solution was found to be highly
stable at 4 °C for over 6 months, no further aggregations and no
needle crystals of PTX were observed. As mentioned before,
Abraxane tends to precipitate 24 h after being reconstituted with
saline. Upon dilution with PBS to 125-fold, to mimic the dilution
by the blood pool through intravenous (iv) injection, needle-like
crystals of PTX were observed in the diluted Taxol (Cremophor
formulation of PTX) but they were not observed in PTX-loaded
PEG5k–CA8 micelle solutions even after 12 months, indicating
that the PTX complex inside these micelles is very stable.
Later Li et al.80 introduced a cross-linked micelle system for
specific delivery of paclitaxel to tumor sites, composed of a
dendritic oligomer of cholic acids attached to one terminus of
the linear PEG through a poly(lysine-cysteine-Ebes) backbone
(Compound 2). Cysteine has been inserted into the linear–den-
dritic structure to achieve a self assembling disulfide-cross-
linking system, so that micelles can be further stabilized to
avoid premature release of the loaded drugs during circulation.
At the tumor sites, the intracellular reductive agents such as
glutathione cleaved the intra-micellar disulfide bonds and
drug release occurred. PTX loading onto the micelles was
carried out by the solvent evaporation method. PTX and the
polymeric structure were first dissolved in chloroform. Then,
the chloroform was evaporated under vacuum to form a thin
film. PBS buﬀer (1 mL) was added to re-hydrate the thin film,
followed by 30 min sonication. The PTX-loaded micelles were
Fig. 7 The chemical structure of PEG5K–CA8 (Compound 1). Reprinted
with permission from ref. 84. Copyright (2009) Elsevier Ltd.
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then cross-linked via O2-mediated oxidization. The CMC value
of 0.67 µM was determined for PTX loaded cross-linked
micelles. The morphology of the PTX loaded cross-linked
micelles was observed to be spherical with uniform sizes
under a TEM. The size of the micelles observed under TEM
was consistent with those measured by DLS (27 nm).80 The
loading capacity of PTX in the cross-linked system was 7.1 mg
mL−1, which was equivalent to a drug/micelle ratio of 35.5%
(w/w). PTX loaded disulfide cross-linked micelles have been
found to be very stable at 4 °C, showing no significant changes
in average particle size and drug content over 8 months. The
stability of the micelles in physiological conditions including
blood was demonstrated by monitoring the particle sizes of
micelles over time. The PTX loaded DCM micelles retained an
average particle size around 30 nm, with uniform and narrow
size distribution, in human plasma for 24 h. Drug release
studies indicated that the PTX release was gradually facilitated
as the GSH concentration increased from its extracellular level
(2 mM) up to the intracellular level (10 mM). This drug release
strategy indicated that premature drug release can be mini-
mized during circulation in vivo, and accelerated release
occurred upon internalization of the micelles into cancer
cells.80
There is one interesting study employing biodegradable
amphiphilic linear–dendritic block copolymers that present
folate in clusters for cell targeting, as a means of selectively
targeting drug-loaded nanocarriers for chemotherapeutics.91
PTX has been loaded into the polymeric micelles noncova-
lently via self-assembly of amphiphilic linear–dendritic copoly-
mers (LDP) composed of the hydrophobic linear polypeptide
block [poly(β-benzyl-L-aspartate)] (Mw = 3000 Da) and the
hydrophilic dendritic polyester-PEG block (Mw = 12 000 Da)
(Fig. 8) (Compound 3). Folate occupied approximately 10% of
the surface (∼4–5 wt% of micelle), leaving the other 90%
exposed as PEG. During assembly, hydrophobic PTX is
entrapped within the micelle core and the polyester-PEG
dendron forms a dense antifouling shell around the micelle.
The PTX-loaded micelles have a hydrodynamic diameter of
∼90 nm and a negative surface charge of −20 mV. It was
shown that PTX remained within the LDP carrier for at least
2 hours following systemic injection, which is suﬃcient time
to allow their distribution to tumors in significant quantity via
EPR. The longer stability observed can be attributed to the low
micelle CMC (CMC of ∼10−8 M) for LDP micelles, making the
system more resistant to dilution eﬀects and destabilization by
in vivo conditions. Increased eﬀective solubility of PTX was
achieved by PTX loading into the linear–dendritic micellar
system with drug-loading weight eﬃciencies up to 40 wt%.
Drug release studies showed enhanced release at lower pH,
caused by breakdown and destabilization of the micelle
structure.91
Qiao et al. have reported a novel linear–dendritic block
copolymer micelle semi-polyamidoamine-b-poly(D,L-lactic acid)
encapsulating hydrophobic docetaxel, a semisynthetic struc-
tural analogue of paclitaxel (Compound 4).92 Hydroxyl-tailed
semi-polyamidoamine dendron (sPA-OH) was synthesized by a
divergent method, in which the growth of a dendron has origi-
nated from a core site. Then, ring-opening polymerization
(ROP) of D,L-lactide was carried out using hydroxyl-tailed
sPA-OH G4.5 (or G3.5) and a catalytic amount of Sn(Oct)2. DTX
has been encapsulated to obtain a linear–dendritic copolymer
by a co-solvent evaporation method. The hydrophobic linear
PLA block formed a micelle inner core that acted as a con-
tainer for insoluble drug DTX, which was subsequently stabil-
ized by the hydrophilic capped polyamidoamine shell. The
highest DTX loading eﬃcacy (80.4%) was achieved for the
copolymer with molecular weight of 11 500 g mol−1 bearing
semi-PAMAM G4.5. CMC of 5.01 mg L−1 and a particle size of
87.4 nm was determined for these DTX loaded micelles. Based
on drug release experiments, it was determined that approxi-
mately 100% of encapsulated DTX was released at pH 5.0,
however this value was about 75% at pHs 6.8 and 7.4, indicat-
ing a facilitated DTX release under acidic conditions, which
can be beneficial to specific drug targeting in vivo (Fig. 9). This
pH dependence was described by the protonation of tertiary
amine groups of semi-PAMAM dendritic block, which leads to
conformational changes and triggers the drug release.92
4.1.2. In vitro evaluations. Investigations of in vitro anti-
cancer activity of the PTX–PEG5k–CA8 NPs (Compound 1), per-
formed on SKOV3-luc-D3 ovarian cancer cells, demonstrated
similar cytotoxic activity against cancer cells as the free drug.84
In vitro cytotoxicity studies of PTX-loaded linear–dendritic
micelles including PEG5k–CA8, PEG
3k–CA4, and PEG
3k–CA8 and
the two clinical formulations of PTX (Taxol and Abraxane) on
SKOV-3 cells demonstrated the IC50 in the range 4.3 to 6.2 ng
mL−1 (Fig. 10).90
Investigation of in vitro antitumor eﬀect of PTX loaded
PEG–poly(lysine-cysteine-Ebes)–cholic acid crosslinked system
(Compound 2), evaluated on SKOV-3 cells, showed less cytotoxi-
city than Taxol.80 This was attributed to the slower release of
PTX within the cell culture media. However, enhanced cytotoxi-
city was achieved through studies on SKOV-3 cells with an
enriched GSH level, which facilitates intracellular drug release
by the cleavage of intra-micellar disulfide bridges.80
Cytotoxicity studies of docetaxel encapsulated semi-poly-
amidoamine-b-poly(D,L-lactic acid) (Compound 4) on human
breast cancer cell lines (MCF-7)92 showed no inhibition of
Fig. 8 Chemical structure of the linear dendritic polymer (LDP) made
from biocompatible and degradable elements (linear polypeptide-[poly-
(β-benzyl-L-aspartate)] block and dendritic polyester–PEG block) (Xn =
12–15). Blue, hydrophilic; red, hydrophobic. Schematic showing the
preparation of paclitaxel (PTX)-encapsulated LDP micelles that do not
present folate or folate clusters for enhanced cell targeting (compound
3). Reprinted with permission from ref. 91. Copyright (2011) Elsevier Inc.
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cellular growth for blank micelles, attributed to reduction/
shielding of the positive charge on the dendrimer surface by
the terminal ester, while DTX-loaded micelles showed equi-
potent anticancer eﬃcacy as control Taxotere® (IC50 2.23 ± 0.15
vs. 1.58 ± 0.11 µg mL−1) (incubation time: 72 h) confirming
semi-PAMAM-b-poly(D,L-lactic acid) as a promising anticancer
drug carrier.92
4.1.3. In vivo evaluations. Evaluation of the anti-tumor
eﬀects of PTX–PEG5k–CA8 NPs (Compound 1) after intravenous
injection in subcutaneous SKOV3-luc tumor bearing mice
showed inhibition of tumor growth for all PTX formulations,
with inhibition being the greatest for PTX–PEG5k–CA8 NPs at
30 mg PTX kg−1.84 However, a second treatment cycle was
initiated on day 38 because of noted tumor progression. A
decreased tumor growth rate was demonstrated after the intra-
venous administration of PTX–PEG5K–CA8 NPs and free drug.
PTX–PEG5k–CA8 exhibited superior anti-tumor activity as com-
pared with Taxol. Based on near infrared fluorescence (NIRF)
imaging, it was found that PTX–PEG5k–CA8 nanoparticles post
i.v. injected into cancer bearing mice had a prolonged blood
circulation time, and preferentially accumulated in tumors,
possibly as a result of EPR eﬀects.84 In vivo biodistribution
(evaluated in nude mice bearing the SKOV-3 ovarian cancer
xenografts) was greatly influenced by the size of the micelles.90
Demonstrated by NIRF images, PTX-loaded PEG3k–CA4
micelles with larger sizes (154 nm) had a very high uptake in
the liver and lungs, but a low uptake in the tumor. On the
other hand, PEG2k–CA4, PEG
5k–CA8 micelles with smaller par-
ticle sizes (17 and 64 nm) showed a better ability to carry the
loaded drug to the tumor sites, which was attributed to EPR
eﬀects. In vivo antitumor eﬀects for PTX-loaded PEG5k–CA8
was found to be superior to those of Abraxane and Taxol, and
cure of the disease was achieved in the group treated with PTX-
loaded PEG5k–CA8 at its MTD dosage (45 mg kg
−1). No weight
loss was observed in mice treated with this nanoformulation,
while consistent weight loss was observed in those treated
with Taxol.90 This system has some significant advantages,
such as nontoxicity of carrier in contrast to the commercial
vehicle of PTX, high drug loading capacity, relatively small sus-
tained drug release profile, superior stability, preferential
accumulation in tumors, similar in vitro cytotoxic activity with
Taxol, and superior in vivo anti-tumor activity as compared
with Taxol.84,90 Enhanced eﬃcacy of PTX encapsulated PEG5k–
CA8 NPs after intravenous injection can be explained as
follows: First, the PEG5k–CA8 nanocarrier may improve the
pharmacokinetic profile of PTX, prolonging its circulation
time, thus resulting in a higher accumulation in tumors due to
EPR eﬀects. Secondly, since PTX encapsulated PEG5k–CA8 NPs
accumulate in the tumor, PTX is released in a sustained
manner so that tumor cells can be exposed to PTX for a longer
time period. Thirdly, PTX encapsulated PEG5k–CA8 NPs have a
relatively small size (50 nm) compared to Abraxane (130 nm),
which may result in deeper penetration into tumor nodules.
This is important as although some larger nanoparticles, such
as liposomes, can be delivered eﬀectively to a solid tumor via
the EPR eﬀect, they would not be distributed suﬃciently to
cancer cells distant from tumor vessels.93 These promising fea-
tures make PTX encapsulated PEG5k–CA8 NPs suitable for
more investigations.84,90
For the PTX encapsulated PEG–poly(lysine-cysteine-Ebes)–
cholic acid crosslinked system (Compound 2),80 according to
noninvasive NIRF optical images, a significant contrast of the
fluorescence signal has been observed between the tumor and
Fig. 9 Self-assembly and multifunctional target delivery of DTX-loaded
polyamidoamine-b-poly(D,L-lactic acid) micelles (Compound 4). Rep-
rinted with permission from ref. 92. Copyright (2013) Elsevier B.V.
Fig. 10 Tumor cell killing of the PTX-loaded PEGmK-CAn micelles in the
SKOV-3 ovarian cancer cells; very similar IC50 values were observed for
all the formulations in in vitro tumor cell killing. Reprinted with per-
mission from ref. 90. Copyright (2010) American Chemical Society.
Review Polymer Chemistry
















































the background at 4 h after administration and was sustained
up to 72 h (Fig. 11, top). Ex vivo imaging at 72 h post injection
further confirmed the preferential uptake of crosslinked
micelles in the tumor compared to normal organs (Fig. 11,
bottom). This is due to the prolonged in vivo circulation time
of the micelles and the size mediated EPR eﬀect. A relatively
high uptake in the liver was observed compared to other
organs, which is likely attributed to the nonspecific clearance
of nanoparticles by the reticuloendothelial system (RES).
Similar biodistribution and tumor uptake of PTX loaded cross-
linked micelles were observed via EPR eﬀects (Table 1).80
Based on in vivo studies evaluated in the subcutaneous
SKOV-3 tumor bearing mice, increased in vivo therapeutic
eﬃcacy has been shown for PTX-loaded crosslinked micelles
compared to the equivalent dose of free drug. This has been
corresponded to the higher amount of PTX that reached the
tumor site via their prolonged circulation time. In addition,
the high glutathione level of the tumor site and particularly
inside the tumor cells facilitated drug release and increased
cytotoxicity.80 Uniform size around of 27 nm for PTX encapsu-
lated the PEG–poly(lysine-cysteine-Ebes)–cholic acid cross-
linked system enables these PTX loaded micelles to take full
advantage of the EPR eﬀect and accumulate at tumor sites. In
addition, the system has the characteristics of superior drug
loading capacity, enhanced micellar stability, prolonged in vivo
circulation time, preferential tumor targeting, and superior
in vivo anti-tumor activity as compared with Taxol. However, a
relatively high uptake in the liver was observed compared to
other organs, which is likely attributed to the nonspecific
clearance of nanoparticles by the reticuloendothelial system
(RES).80
In the case of polymeric vehicle composed of hydrophobic
linear polypeptide block [poly(β-benzyl-L-aspartate)] and hydro-
Fig. 11 In vivo and ex vivo near infra-red ﬂuorescence (NIRF) optical
imaging. Top: In vivo NIRF optical images of a SKOV-3 xenograft bearing
mouse were obtained with a Kodak imaging system at diﬀerent time
points after i.v. injection of PEG–poly(lysine-cysteine-Ebes)–Cholic acid
co-loaded with PTX and DiD; bottom: ex vivo NIR image of dissected
organs and tumor was obtained at 72 h after injection. Reprinted with
permission from ref. 80. Copyright (2011) Elsevier Ltd.
Table 1 Paclitaxel-encapsulated linear–dendritic block copolymers
Carrier
Size
(nm) CMC In vitro activity In vivo activity Advantages Ref.
PEG5K–CA8 56 1 μM IC50 = 4.3 ng mL−1 on SKOV3-
luc-D3 ovarian cancer cells
Superior anti-tumor activity
for PTX–PEG5k–CA8 as




High drug loading level,
nontoxic carrier, high drug
loading capacity, relatively small
sustained drug release profile,
superior stability, preferential
accumulation in tumors,






27 0.67 µM Less cytotoxicity compared to
Taxol on SKOV-3 cells, but
higher cytotoxicity compared
to Taxol with an enriched
GSH level
Increased in vivo therapeutic
eﬃcacy compared to the
equivalent dose of free drug
in the subcutaneous SKOV-3
tumor bearing mice
Superior drug loading capacity,
enhanced micellar stability,
prolonged in vivo circulation
time, preferential tumor
targeting, and superior in vivo






90 10−8 M Enhanced uptake of ligand-
clustered micelles in ovarian
tumor cells
Higher in vivo antitumor
eﬃcacy for the folate-bearing
linear–dendritic micelles
compared to free PTX in
FR-expressing KB xenograft
model in nude mice
Suitable circulation half-life,
resistance to dilution eﬀects
and destabilization by in vivo
conditions, increased targeting








IC50 = 2.23 ± 0.15 µg mL
−1 on
human breast cancer cell lines
(MCF-7), equipotent anticancer
eﬃcacy as control Taxotere
1.53 fold higher half-life of
























































philic dendritic polyester-PEG block (Compound 3),91 after
intravenous injection in BALB/c mice without tumors, distri-
bution half-lives (t1/2, distribution) of the encapsulated PTX
(2.5 wt%) and free PTX (2.5 wt% equivalent) were 1.72 ±
0.2 hour, and 0.61 ± 0.4 hour, and their elimination half-lives
(t1/2, elimination) were 9.06 ± 2 hours, and 4.32 ± 3 hours, respect-
ively, indicating a much higher bioavailability of the PTX-
loaded LDP micelles compared to the free drug. This can be
attributed to the low CMC of micelles, making the system
more resistant to dilution eﬀects and destabilization by in vivo
conditions. Also 10–12% weight loss was revealed in mice
receiving free-PTX and signs of hair loss were observed after
six injections. No signs of toxicity were shown in mice receiv-
ing PTX-encapsulated injections. In vivo antitumor eﬃcacy
investigations, evaluated in the FR-expressing KB xenograft
model in nude mice, showed that the folate-bearing linear–
dendritic micelles (PTX dosage = 2.5 mg kg−1) are as eﬀective
as a higher dose of free PTX (10 mg kg−1). Comparison of the
tumor killing eﬀects between folate-targeted and untargeted
micelles (PTX dosage = 2.5 mg kg−1) determined the higher
antitumor eﬃcacy for the folate-targeted LDP system. This was
attributed to more eﬃcient entering of the folate targeted
micelles into tumor cells from the extracellular space, through
FR-mediated uptake, and subsequent intracellular release of
the drug.91 The measured circulation half-life of PTX encapsu-
lated [poly(β-benzyl-L-aspartate)]-block-dendritic polyester-PEG
was significantly higher than the values reported in preclinical
trials for PTX loaded PEG-block-poly(D,L-lactide) linear block
copolymers in the literature.94 The longer stability, due to low
micelle CMC, more resistance to dilution eﬀects and destabili-
zation by in vivo conditions, increased targeting of the micelles
to FR-expressing cells, increased accumulation over a 5-day
period, and the potency of the therapy with a low PTX dose of
2.5 mg kg−1 make this system promising for antitumor treat-
ment. For achieving a relatively similar eﬀect, this dosage
regimen is much lighter in comparison to other studies invol-
ving folate-mediated therapy.95–97 However, the data also
suggest a gradual loss of PTX from the micelles at longer time
points via slow leakage of the drug from the interior of the
micelle, and future design of the system may be applied to
further address this issue.91
Pharmacokinetic study in Sprague–Dawley (SD) rats illus-
trated that semi-polyamidoamine-b-poly(D,L-lactic acid)
micelles (Compound 4) prolonged DTX retention in blood cir-
culation (1.737 h) in comparison to Taxotere® (commercial
vehicle of DTX) (1.231 h), and the half-life of DTX in micelles
was 1.53 fold higher than that of the Taxotere® control.92 A
plausible explanation was that ester-terminated hydrophilic
dendrons and a dense micelle structure were capable of pre-
venting the drug molecules from being easily eliminated from
the physiological environment. Investigation of intracellular
uptake capacity evaluated in MCF-7 cells demonstrated that
fluorescent dye C6 labeled semi-polyamidoamine-b-poly(D,L-
lactic acid) micelles had been internalized into the cytoplasm.
Previous studies indicated that multivalent dendrimers
enhanced membrane adhesion and disruption.98 The multi-
valent dendritic surface of linear–dendritic semi-polyamidoa-
mine-b-poly(D,L-lactic acid) might also increase binding sites
with the membrane and facilitate micelle uptake. Further
studies are needed to elucidate the uptake mechanisms of
semi-polyamidoamine-b-poly(D,L-lactic acid) micelles. Gener-
ally, low CMC would be beneficial to semi-polyamidoamine-b-
poly(D,L-lactic acid) micelles in order to avoid dilution in the
blood circulation. Some other advantages such as biocompat-
ibility, improved cellular uptake, and facilitated anticancer
drug release under acidic conditions make linear–dendritic
semi-polyamidoamine-b-poly(D,L-lactic acid) useful for anti-
cancer drug delivery. However, its safety and eﬃcacy in che-
motherapy should be further studied.92
4.2. Paclitaxel-conjugated linear–dendritic block copolymers
4.2.1. Physicochemical properties. A linear–dendritic tar-
geting system for PTX delivery has been reported by Clementi
et al.,8 employing alendronate (ALN), a bone-targeting agent
used for the treatment of osteoporosis and bone metastases.
A PEG–dendrimer–ALN structure has been designed using β-glu-
tamic acid as a symmetric bicarboxylic branching unit and
linking of ALN to carboxylic PEG–dendrimer groups. Coupling
of PTX to PEG–dendrimer–ALN through ester linkage yielded
the linear–dendritic ALN-mediated bone targeting prodrug
(Compound 5) (Fig. 12).
This design leads to an amphiphilic conjugate, with PTX
being highly hydrophobic and ALN being hydrophilic. The
spatial separation of these drugs, besides oﬀering the possi-
bility to form self-assembled micelles, will maintain all ALN
molecules exposed to the water, promptly available for binding
to the bone mineral HA.8 The content of ALN and PTX in the
PEG–(β-Glu) dendrimer was determined as 11% w/w and 4.7%
w/w, respectively. The mean hydrodynamic diameter of PTX–
PEG–(β-Glu) dendrimer–ALN conjugates was 200 nm. Investi-
gation of drug release showed that the hydrolysis rate of the
ester bond between PTX and the polymer was higher in both
Fig. 12 Chemical structure of PTX conjugated PEG–(β-Glu) dendri-
mer–ALN (Compound 5). Reprinted with permission from ref. 8. Copy-
right (2011) American Chemical Society.
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plasma and buﬀer solution at physiological pH (7.4), com-
pared to that in buﬀer solution at lysosomal pH (pH 5). This
phenomenon indicated that PTX is released by a hydrolytically
based mechanism without a significant contribution of
esterases. The stability of PTX–PEG–(β-Glu) dendrimer–ALN
was evaluated in buﬀer solutions at physiological pH (7.4), at
lysosomal pH (5), and in mice plasma. At pH 7.4 and in
plasma, about 50% of the PTX–PEG–ALN conjugate was
degraded within the first 1 h; the remaining conjugate was
degraded within 24 h. The stability of the conjugate micelles,
monitored at 37 °C for 24 h by DLS, was in line with the kine-
tics of PTX release. The micelles of PTX–PEG–ALN conjugates
preserved the same size for 24 h when incubated in buﬀer at
pH 5, whereas at pH 7.4 the same micelles were stable for 3 h,
then the PTX release from the conjugates destabilized the
system.8
4.2.2. In vitro evaluations. ALN-mediated binding capacity
of PEG–(β-Glu) dendrimer–ALN and PTX conjugated PEG–
(β-Glu) dendrimer–ALN (Compound 5) to bone mineral was
evaluated in vitro, employing HA mineral mimicking bone
tissue.8 By fast protein liquid chromatography (FPLC) analysis,
it was revealed that, following 5 min of incubation, 80% or
90% of PTX–PEG–dendrimer–ALN or PEG–ALN conjugates,
respectively, were bound to HA and reached a plateau. On the
other hand, non-targeting PEG could not bind to HA after
60 min of incubation, confirming the role of ALN in the bone
targeting process.
Illustrated by in vitro rat red blood cell (RBC) hemolysis
assay, PTX–PEG–(β-Glu) dendrimer–ALN showed no hemolytic
activity at up to 5 mg mL−1. Regarding significant hemolytic
activity of the commercial solubilizing vehicle of PTX, PEG–
(β-Glu) dendrimer–ALN can be suggested as a promising
carrier for PTX. In vitro cytotoxicity assay on PC3 human pros-
tate cancer cells exhibited similar IC50 for PTX–PEG–dendri-
mer–ALN and free PTX (25–60 nM).8
4.2.3. In vivo evaluations. The pharmacokinetic studies of
PTX dissolved in 1 : 1 : 8 ethanol–Cremophor EL–saline and
PTX–PEG–(β-Glu) dendrimer–ALN (Compound 5) showed an
improved Pharmacokinetic Profile in Mice.8 After adminis-
tration of free PTX, high levels of the drug were recorded,
however at 5 min post-injection the PTX concentration
decreased dramatically, and it was not detectable at 60 min.
On the contrary, the conjugates showed a marked half-life
prolongation, with detectable levels of PTX after 24 h for
PTX–PEG–(β-Glu) dendrimer–ALN. In particular, elimination
half-lives (T1/2β) were 15.1 and 85.5 min for PTX and PTX–PEG–
(β-Glu) dendrimer–ALN, respectively.8
PTX–PEG–(β-Glu) dendrimer–ALN conjugate was designed
for strong bone tropism and fast drug release. Therefore, with
PTX–PEG–(β-Glu) dendrimer–ALN conjugate, a cathepsin
B-cleavable linker might not be suitable because the derivative
in vivo will bind to the bone HA matrix. The high aﬃnity to the
bone originating from the presence of a bisphosphonate in the
conjugate can aﬀect the conjugate internalization into cancer
cells and consequently slow the rate of PTX release, if a cathep-
sin B-cleavable linker is used. Cathepsin B is over-expressed in
lysosomes of many types of tumor cells, but is also secreted to
the extracellular matrix. In general, enzymatic cleavage is
eﬃcient when slow and controlled drug release is required.
When a fast release is desired, a diﬀerent mechanism, such as
hydrolysis, is necessary. Therefore, a PTX–polymer hydrolysis
at physiological conditions is preferred because it allows drug
release in the surroundings of bone metastasis, where the con-
jugate will fast accumulate.
PTX was linked to PEG through an ester linkage exploiting
a succinimidyl spacer, which releases the drug at physiological
pH. The hydrolysis rate of the ester bond between the drug
and the polymer was higher in buﬀer at pH 7.4 than in pH
5. Interestingly, the incubation in plasma showed a drug
release comparable to that in buﬀer at pH 7.4, suggesting that
PTX is released by a hydrolytically based mechanism without a
significant contribution of esterases. Besides nontoxic build-
ing blocks, the derivative can target bone neoplasms by dual-
targeting as follows: (1) through ALN (active mechanism), and
(2) by exploiting the EPR eﬀect (passive mechanism), which is
due to the atypically leaky tumor blood vasculature, which
enhances tumor accumulation of the conjugate thanks to its
increased size with respect to the free drug (Table 2).8
5. Doxorubicin
Doxorubicin (DOX) is a widely used anticancer drug in the
treatment of many types of cancer, including hematological
malignancies, many types of carcinoma, and soft tissue sarco-
mas. DOX is known to interact with DNA by intercalation and
to inhibit the biosynthesis of macromolecules.67,99–101
Table 2 Paclitaxel-conjugated linear–dendritic block copolymers






200 na Similar IC50 for PTX–PEG–dendrimer–
ALN and free PTX (25–60 nM) on
PC3 human prostate cancer cells
na Nontoxic carrier building blocks, half-life
prolongation of conjugates, targeting bone
neoplasms, fast drug release in the surroundings of
bone metastasis
8
a n: not reported.
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However, drawbacks such as poor water solubility, poor
penetration in vitro and in vivo, and dose dependent side-
eﬀects such as cardiotoxicity, caused by lack of tumor selecti-
vity, limit its application in chemotherapy.101–103 Several tech-
niques have been used to enhance tumor targeting and reduce
the toxicity without sacrificing eﬃcacy. The use of macro-
molecular drug carriers such as liposomes,104 polymeric
micelles,105 dendrimers106 and linear–dendritic copolymers107
is the focus of research. One clinical example is DoxilVR, a
polyethylene glycol (PEG) containing liposomal formulation of
DOX that limits the cardiotoxicity while maintaining the same
survivability as the free drug.102
5.1. Doxorubicin-encapsulated linear–dendritic block
copolymers
5.1.1. Physicochemical properties. Gillies and Fréchet
have reported DOX encapsulation in acid-sensitive linear–den-
dritic micelles. The linear–dendritic structure was composed
of a PEO block and a G3 polyester dendrimer of 2,2-bis(hydro-
xymethyl) propanoic acid units bearing cyclic acetals of 2,4,6-
trimethoxybenzaldehyde (Compound 6 in Fig. 13). DOX was
loaded into micelles by an oil/water emulsion method in
which chloroform was used as the organic phase, and 3 equiv
NEt3 was used relative to DOX, as the drug is known to par-
tition most eﬀectively into the chloroform phase and into the
micelle upon deprotonation of the glycosidic amine. Release
of the drug occurred through disruption of the micelle caused
by hydrolysis of the cyclic acetals at acidic pH and change in
micelle solubility.107
A drug loading of approximately 12 wt% was determined
according to absorbance using UV-visible spectroscopy. The
DOX-loaded micelles demonstrated the particle size of 35 nm
and a small fraction of aggregates in the size range
200–400 nm was observed. Additionally, a CMC value of 40 mg
L−1 was determined for this system. At pH 7.4, the micelles
were stable over several days, with no significant changes in
the size distribution over this time period. In contrast, over
several hours at pH 5.0, the size of the DOX-loaded micelles
increased and the fraction of aggregates in the population
became greater. This aggregation probably occurred upon dis-
ruption of the micelles due to acetal hydrolysis and was facili-
tated by the tendency of DOX to form aggregates by π-stacking.
Investigation of drug release at diﬀerent pH values demon-
strated a pH-dependent mode of release of DOX from copoly-
mer 1. After 24 h, drug release of more than 80%, about 40%
and about 30% was observed at pH values of 4.0, 5.0 and 6.0,
respectively, while at pH 7.4 the system was very stable with
less than 10% of the DOX being released over 72 h. These
results indicated that the hydrolysis of the pH-sensitive acetals
likely plays a role in the mode of drug release, leading to the
selective release of DOX in mildly acidic physiological environ-
ments (such as tumor tissues). In addition, the increased stabi-
lity of the pH-sensitive system at pH 7.4 is advantageous so
that DOX will not be released during blood circulation, thus
avoiding the undesirable organ accumulation and toxicity
associated with the free drug.107
A newly developed telodendrimer platform, consisting of
PEG as the linear block and cholic acid attached to the amine
terminus of lysine as the dendritic block, has been employed
to prepare DOX micellar formulations for the targeted delivery
of DOX to lymphoma.108 As mentioned before,84 PEG5k–CA8
micellar NPs provided a suitable drug delivery system for PTX
(a hydrophobic drug) in the treatment of cancer. In their
study, Xiao et al. showed that the delivery of DOX using this
nanocarrier is limited by the relatively low drug loading
capacity and poor stability.108 Using the dry-down method,
PEG5K–CA8 telodendrimers can eﬃciently encapsulate hydro-
phobic drug DOX into the core of the micelles (Compound 7).
PEG5k–CA8 telodendrimer, along with diﬀerent amounts of
neutralized DOX, were first dissolved in CHCl3–MeOH, mixed,
and evaporated on a rotavapor to obtain a homogeneous dry
polymer film. The film was reconstituted in 1 mL phosphate
buﬀered solution (PBS), followed by sonication for 30 min,
allowing the sample film to disperse into the micelle
solution.108
Based on their report, PEG5k–CA8 micelle was found to have
a DOX loading capacity of 8.2% w/w. Another telodendrimer
with a similar structure, PEG2k–CA4, was suggested to encapsu-
late DOX, which resulted in a higher drug loading capacity of
14.8% w/w. The particle sizes of DOX-loaded PEG5k–CA8 and
PEG2k–CA4 micelles were in the range 12–17 nm in diameter.
Drug release profiles illustrated biphasic patterns for both
DOX-loaded PEG2k–CA4 and PEG
5k–CA8 micellar formulations.
It was indicated that 50% DOX cumulative release occurred
from DOX–PEG5k–CA8 during the first 6 h. This value was 35%
for DOX–PEG2k–CA4 over the same time. After the initial fast
release, the slow linear release was observed for both systems
over the next 7 days. However, the DOX release rate from DOX–
PEG2k–CA4 micelles was significantly slower than that from
DOX–PEG5k–CA8 micelles, reflecting the better stability and
stronger interaction between the nanocarrier and the drug in
DOX–PEG2k–CA4. Particle size monitoring confirmed the stabi-
lity of DOX–PEG2k–CA4 in physiological conditions. As shown
by DLS measurements (Fig. 14), DOX–PEG2k–CA4 micelles as
Fig. 13 Hydrolysis of acetals on the dendrimer periphery of the
micelle-forming copolymer 6 leads to a solubility change designed to
disrupt micelle formation and trigger the release of the drug. Reprinted
with permission from ref. 107. Copyright (2005) American Chemical
Society.
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well as Doxil® were able to maintain their initial particle sizes
over 72 h incubation in the presence of 50% FBS. In contrast,
DOX–PEG5k–CA8 micelles started to form bigger aggregates
(around 300 nm) after a 6-hour incubation with 50% FBS.108
Wu et al. developed dendritic–linear block copolymer-modi-
fied magnetic iron oxide nanoparticles as a carrier for DOX,
which displays thermosensitive drug release behaviors.109 In
their study, magnetic iron oxide (Fe3O4) nanoparticles were
first prepared by organic solution-phase decomposition of the
iron precursor at high temperature. The prepared magnetic
iron oxide nanoparticle surfaces were capped by the propargyl
focal point polyamidoamine (PAMAM)-type dendron, having
four carboxyl acid end groups. Then, by a click reaction, the
surface initiator was introduced onto the propargyl group, and
using two-step surface-initiated ATRP, poly(2-dimethyl-
aminoethyl methacrylate) (PDMAEMA) chains and poly(N-iso-
propylacrylamide) (PNIPAM) chains were sequentially
introduced onto the magnetic nanoparticle surfaces resulting
in PAMAM-b-PDMAEMA-b-PNIPAM block copolymer-modified
magnetic iron oxide nanoparticles. At the final step, to
increase stability of the nanoparticles and reverse aggregation,
a cross-linking reaction between PDMAEMA block and 1,2-bis-
(2-iodoethoxy)ethane (BIEE) was carried out (Fig. 15). After the
crosslinking reaction, the magnetic nanoparticles were stabil-
ized in water, forming a stable brown solution and no precipi-
tation occurred for 4 months. However, non-crosslinked Fe3O4-
PAMAM-b-PDMAEMA-b-PNIPAM nanoparticles could be only
stabilized in water for 2 months. It was also verified that the
cross-linking reaction could be helpful to stabilize magnetic
iron oxide nanoparticles. DLS measurements of freshly cross-
linked block copolymer-modified nanoparticles diluted in
water provided an average hydrodynamic diameter of particles
in solution equal to ∼32 nm. DOX has been loaded into the
PAMAM-b-PDMAEMA-b-PNIPAM shell of the modified nano-
particles with a loading eﬃciency of 22.7% (Compound 8).109
Investigation of drug release behaviour of DOX-loaded
nanoparticles demonstrated the cumulative release amounts
of 26.8% and 13.7% at 25 °C and 37 °C, respectively (pH = 7.4,
5 h). This phenomenon was also observed after 24 h with the
cumulative release amounts of 41% and 26% at 25 °C and
37 °C, respectively. It was noted that the cumulative release
amount was higher at 25 °C than at 37 °C, confirming thermo-
sensitive release caused by PNIPAM block chains in the col-
lapsed and hydrophobic conformation at 37 °C above the
LCST, which can retard drug release.109
Also, superparamagnetic iron oxide nanoparticles (SPIONs),
grafted with a DOX-loaded water-soluble dendritic–linear-
brush-like triblock copolymer, polyamidoamine-b-poly(2-(di-
methylamino)ethyl methacrylate)-b-poly(poly(ethylene glycol)
methyl ether methacrylate) (PAMAM-b-PDMAEMA-b-PPEGMA),
have been reported as a pH-sensitive drug delivery system
(Compound 9).110 Immobilization of an ATRP macroinitiator,
containing PAMAM G2-typed dendron, on the surface of Fe3O4
nanoparticles has been carried out according to the reported
procedure in the literature.109 Then, water soluble dendritic–
linear-brush-like triblock copolymer (PAMAM-b-PDMAEMA-b-
PPEGMA)-grafted SPIONs have been prepared by gradual
growing of PDMAEMA and PPEGMA from nanoparticle sur-
faces using the ATRP “grafting from” approach. After removal
of the Fe3O4 cores with hydrochloric acid, Mn and PDI of the
grafted copolymers PAMAM-b-PDMAEMA-Br were 3900 g mol−1
and 1.08, respectively. For the final grafted copolymers
PAMAM-b-PDMAEMA-b-PPEGMA, Mn and PDI were 26 300 g
mol−1 and 1.25, respectively. DLS measurement confirmed
Fig. 14 DLS measurement of particle size change of DOX-loaded
PEG5k–CA8 micelles, and Doxil® in 50% FBS over time at 37 °C. DOX
loading level was 2 mg ml−1 DOX in 20 mg ml−1 telodendrimer, respect-
ively. Reprinted with permission from ref. 108. Copyright (2011) Elsevier
B.V.
Fig. 15 Synthesis and surface modiﬁcation of superparamagnetic
Fe3O4 nanoparticles (Compound 8). Reprinted with permission from ref.
109. Copyright (2011) The Royal Society of Chemistry.
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that the obtained dendritic–linear-brush-like triblock copoly-
mer-grafted SPIONs had a uniform hydrodynamic particle size
of average diameter less than 30 nm. For drug loading, DOX–
HCl (2.0 mg) was dissolved in methanol (4.0 mL), and triethyl-
amine (25 µL) was then added into the solution to remove
hydrochloride. Drug loading was done by drop-wise addition
of the DOX solution with stirring to 3 mL Fe3O4-PAMAM-b-
PDMAEMA-b-PPEGMA nanoparticles in methanol (concen-
tration of 2.5 mg mL−1). The mixture was shaken for 24 h in
the dark at room temperature to allow the drug partition into
the polymer shell. The modified Fe3O4-PAMAM-b-PDMAEMA-
b-PPEGMA nanoparticles possessed the thicker shell of poly-
mers, which is beneficial to enhance hydrophobic interactions
and hydrogen binding with DOX and improve the loading
capacity.110 In vitro drug release experiments showed a pH-
responsive drug release behavior for DOX-loaded nanoparti-
cles. The cumulative release amounts of DOX within 48 h at
pH 4.7, 7.4 and 11.0 are 83.1%, 64.7% and 8.3%, respectively.
The higher release at pH 4.7 has been attributed to decreased
hydrogen bond interaction between PDMAEMA and DOX due
to the protonation of PDMAEMA chains and DOX at pH 4.7.
On the other hand, PDMAEMA chains tend to swell due to the
protonated tertiary amino groups at pH 4.7, which is beneficial
to accelerate DOX release.110
The antitumor eﬀect of doxorubicin encapsulated into
amphiphilic linear–dendritic hybrids of PEG–Gn–PCL (n = 0, 1,
2) (Compound 10) has been evaluated in MDA-MB-231 and
MDA-MB-468 breast adenocarcinomas.102 The linear com-
ponent of PEG has been employed as the hydrophilic block
with a dendron branched poly(ε-caprolactone) (PCL) as the
hydrophobic one. The dendrons have been prepared from the
2,2-bis(methylol)propionic acid (bisMPA) building block,
bearing click chemistry moieties in the focal point to attach
PEG (Fig. 16).
The amphiphilic PEG–Gn–PCL structures were capable of
forming self-assembled micelles with diameters of about
100 nm. Sequestering doxorubicin achieved a loading
eﬃciency up to 22% for PEG2k–G1–PCL30. It has been demon-
strated that the loading of DOX resulted in aggregation of the
smaller particles into larger ones, suggesting that some PEG
components used in these linear–dendritic hybrids are not
suﬃciently large to eﬀectively shield the particle from particle–
particle interactions. Also increasing the generation of the
dendron to two resulted in a substantial loss of loading
eﬃciency down to 8% (PEG5k–G2–PCL30).102 This has been
attributed to the eﬀect of lower crystallinity, due to the eﬀect
of the dendritic branching, resulting in a less densely packed
hydrophobic core. Also, the incorporation of DOX in a nano-
scale confined crystalline core will reduce the crystallinity
further. Drug release studies revealed that the mode of release
was independent of block portion and dendrimer generation
employed in the micelle construction, suggesting that the core
material did not influence the diﬀusion path of the drug from
the core. The release of about 60% at 6 h and more than 80%
at 24 h has been shown for all evaluated systems.102
Recently carbon nanotubes have been introduced as prom-
ising materials for the delivery of drugs, RNA, DNA, peptides
and other biologically active molecules into cells, because of
the ability to cross cell membranes.111–114 Despite the great
potential of carbon nanotubes (CNTs) in anticancer drug deliv-
ery, concerns regarding their carcinogenicity, ineﬃcient dis-
persion in aqueous solutions and biological activity in vivo still
remain. One important and feasible route to overcome these
problems is modification of CNTs with polymers, which are
widely studied and play a vital role in biological and biomedi-
cal fields, especially in drug delivery.115 Two methods are used
to modify the CNTs by polymers based on either physical inter-
actions or chemical bonding and are so called “noncovalent”
or “covalent” approaches, respectively. The noncovalent
approach is based on poor van der Waals interactions between
CNTs and polymers and includes dispersion with the low
molar mass polymers, polymer wrapping and polymer
adsorption.116–118 In the covalent approach, molecules or
macromolecules are grafted onto the surface of CNTs through
chemical linkages, raising the solubility of CNTs even with a
low degree of functionalization. Covalent attachment of
polymer chains to the surface of CNTs can be accomplished by
either “grafting to” or “grafting from” methods.114,115,119–124
We proved that polymers not only raise the functionality, bio-
compatibility and water solubility of CNT but also are able to
change the CNT conformations dramatically. A drug carrier
composed of polyglycerol–poly(ethylene glycol)–polyglycerol
(PG–PEG–PG) ABA linear–dendritic copolymer and CNTs was
designed and potential application of the obtained structure
to load and transport the anticancer drug DOX was investi-
gated (Compound 11).125 Fig. 17 illustrates the schematic
structure of the used linear–dendritic copolymer. It has been
observed that noncovalent interactions between (PG–PEG–PG)
linear–dendritic copolymer and CNTs lead to the conformation
alteration of CNTs from an extended toward a closed state due
Fig. 16 Chemical structure of PEG–G2–PCL (Compound 10). Reprinted
with permission from ref. 102. Copyright (2011) Wiley Periodicals, Inc.
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to liposome-like nanocapsule (LLNs) formation. The size of
the PG–PEG–PG/MWCNT LLNs filled with DOX molecules was
estimated to be 350 nm.
Loading capacities for the PG–PEG–PG/MWCNT LLNs were
determined by HPLC as 2.2 grams to one gram of LLNs.125
Poor water solubility and low functionality are two critical
factors that limit the biomedical applications of CNT/
γ-Fe2O3NP hybrid nanomaterials. Non-covalent method for
improving solubility is based on supramolecular interactions
between CNTs and polymers and includes polymer wrapping
or adsorption. In this method, the structure of CNTs is not
damaged as much as in the covalent method, but its disadvan-
tage is the low functionality of the final product. A new
method to improve the functionality and water solubility of
CNT/γ-Fe2O3NP hybrid nanomaterials without damaging their
structure has been reported by using linear–dendritic
copolymers.126–128
An example of non-covalent interactions between CNTs and
linear–dendritic copolymers is hybrid nanostructure-based
magnetic drug delivery systems (HNMDDSs), including carbon
nanotubes, magnetic iron oxide nanoparticles, and linear–den-
dritic PAMAM–PEG–PAMAM copolymer.32 PAMAM–PEG–
PAMAM was employed to solubilize and functionalize carbon
nanotubes through supramolecular interactions. The resulting
Fe3O4-MWCNTs/PAMAM–PEG–PAMAM hybrid nanomaterials
were utilized to encapsulate DOX (through π–π stacking) with a
loading capacity of about 3.3% (Compound 12). According to
dynamic light scattering, the average diameter of DOX loaded
Fe3O4-MWCNTs/PAMAM–PEG–PAMAM nanomaterials in water
was 207 nm and aqueous solutions of hybrid nanomaterials
were stable over several weeks at room temperature.32
Based on VSM curves, the saturation of magnetization
of Fe3O4-MWCNTs/PAMAM–PEG–PAMAM and DOX/Fe3O4-
MWCNTs/PAMAM–PEG–PAMAM were slightly smaller than
that of Fe3O4-MWCNTs, but both had similar properties that
were close to the superparamagnetic behavior, indicating that
the magnetic properties of Fe3O4-MWCNTs did not lose by the
non-covalent interaction of DOX and PAMAM–PEG–PAMAM on
their surfaces. With this unique property, DOX/γ-Fe3O4-
MWCNTs/PAMAM–PEG–PAMAM can be used as a promising
material in many fields such as cancer diagnosis and therapy
(Fig. 18).32
Using copper(I)-catalyzed azide–alkyne cycloaddition
(CuAAC)-based click chemistry and “dendrone-first” method,
Hed et al. synthesized a set of dendritic linear hybrid materials
composed of linear PEG and dendritic aliphatic bis-MPA poly-
esters (G4).129 To achieve amphiphilic structures, the bis-MPA
layer also introduced hydrophobicity, using benzylidene-pro-
tected bis-MPA anhydride. Finally, the convergent coupling
was carried out between monofunctional PEG5k-acetylene and
azide functional dendrons azide-[G4]-(Bz)8 by CuAAC click
chemistry (Fig. 19).
Increased sizes of the micelles has been demonstrated after
encapsulation of DOX into the amphiphilic PEG-[G4]-(Bz)8
(diameters reported for the intensity average DLS data: 88 nm
for PEG-[G4]-(Bz)8, and 300 nm for DOX loaded PEG-[G4]-(Bz)8
Fig. 17 (a) Schematic representation of PG–PEG–PG ABA type linear
dendritic copolymer, (b) schematic representation of noncovalent inter-
actions between linear–dendritic copolymers and the surface of CNTs
that lead to new hybrid nanomaterials with improved properties, (c) AFM
image of PG–PEG–PG/MWCNT liposome-like nanocapsules containing
encapsulated DOX molecules. The highlighted object in the top-left part
of image, by a black line, shows the MWCNTs (Compound 11). Reprinted
with permission from ref. 125. Copyright (2012) The Royal Society of
Chemistry.
Fig. 18 The schematic representation of HNMDDSs including carbon
nanotubes, magnetic iron oxide nanoparticles, and linear–dendritic
PAMAM–PEG–PAMAM copolymer (Compound 12). Reprinted with per-
mission from ref. 32. Copyright (2013) Iranian Chemical society.
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(Compound 13)) indicating that the PEG length used for these
materials is not suﬃcient to suppress aggregation. A loading
eﬃciency of 51% has been found for DOX-loaded PEG-[G4]-
(Bz)8. Drug release studies exhibited a burst release during the
first 12 h, under which at least 80% of the DOX was released,
and around 90% of the content was released within 72 h. This
phenomenon has been attributed to the low capacity of the
hydrophobic domain to act as a diﬀusion barrier. It was
suggested that increasing the PEG molecular weight should be
noted to restrict aggregation and achieve better controlled
release kinetics.129
Recently, the stimuli-responsive polymeric micelles and
assemblies that are triggered by the light as external stimuli
have been widely investigated for “on–oﬀ” drug delivery
systems and “on-demand” nanomedicines, because of their
assembly/disassembly switch. Compared with UV light, the
near infrared (NIR) light between 750 and 1000 nm can pene-
trate up to a centimetre in depth of the tissues with less
damage and scattering, which makes the NIR-sensitive nano-
medicines promising as noninvasive and on-demand thera-
peutic candidates.130,131
Sun et al. have reported near-infrared (NIR) light-responsive
linear–dendritic amphiphiles consisting of linear PEO and
dendritic PAMAM (third-generation, D3) decorated with diazo-
naphthoquinone (DNQ) employed for NIR-triggered release of
the anticancer drug doxorubicin (Compound 14).132 In their
synthetic route, the reaction between the alkyne focal point
PAMAM Dendron (D3: bearing eight primary amine groups)
and DNQ sulfonyl chloride has been utilized to yield the click-
able dendron D3DNQ (with eight DNQ groups), which has
then been click conjugated with azide-terminated PEO (5 K) to
produce the final linear–dendritic amphiphiles (Fig. 20). It has
been demonstrated that under NIR (e.g. 808 nm) irradiation,
the hydrophobic diazonaphthoquinone (DNQ) molecule trans-
forms into the hydrophilic photoproduct 3-indenecarboxylic
acid (pKa = 4.5) via the Wolﬀ rearrangement,
132 which would
result in the disassembly and/or disruption of DNQ-containing
micelles in PBS (e.g. pH 7.4).133–135
Besides having a common spherical morphology, PEO5K–
D3DNQ micelles had a DLS-determined diameter of ∼90 nm.
In addition, the average size of the micelles slightly changed
over 25 days in PBS (10 mM, pH 7.4) at 37 °C, suggesting that
they were dynamically stable in vitro. A DOX-loading capacity
of about 20 wt% has been determined for PEO5K–D3DNQ
micelles. Determined by DLS, the DOX-loaded PEO5K–D3DNQ
micelles increased from 90 nm (blank micelles) to 160 nm.
These results also suggested that the hydrophobic DOX drug
was indeed encapsulated into the hydrophobic core of the
micelles. Similar to their blank counterparts, the DOX-loaded
micelles presented a nearly spherical morphology. In vitro
drug release studies demonstrated a NIR-triggered drug
release profile for DOX-loaded PEO5K–D3DNQ micelles. The
accelerated drug-release was exhibited after 10 min of 808 nm
irradiation. It was found that 90% of DOX was released within
about 210 h, compared with that without irradiation (about
420 h). Moreover, the apparent drug-release rate of DOX-
loaded PEO5K–D3DNQ micelles accelerated nearly 8 times
after 30 min of 808 nm irradiation compared to 10 min radi-
ation, indicating NIR-responsive DOX release from the
nanomedicines.132
5.1.2. In vitro evaluations. Based on in vitro cytotoxicity
investigations evaluated on MDA-MB-231 breast cancer cells,
IC50 of approximately 3 µg mL
−1 and 0.8 µg mL−1 has been
determined for DOX-loaded PEO-block-G3 polyester dendrimer
of 2,2-bis(hydroxymethyl)propanoic acid units bearing cyclic
acetals of 2,4,6-trimethoxybenzaldehyde micelles (Compound
6) and free drug, respectively.107 The somewhat lower toxicity
of the micelle system may result from the gradual release of
DOX within the cell and from diﬀerences in the released
drug’s cellular localization relative to the free drug. However,
IC50 of 3 µg mL
−1 for DOX-loaded micelles indicated the
release of free and active DOX in the cells and indicated
Fig. 19 Schematic structure of DL PEG-[G4]-(Bz)8 (Compound 13).
Reprinted with permission from ref. 129. Copyright (2013) Wiley Period-
icals, Inc.
Fig. 20 Synthesis of linear–dendritic amphiphiles PEO–PAMAM (D3)
DNQ by click chemistry (Compound 14). Reprinted with permission
from ref. 132. Copyright (2013) The Royal Society of Chemistry.
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encouraging therapeutic potential of the system. Drug localiz-
ation in intracellular organelles has been proved for DOX-
loaded micelles by Laser scanning confocal microscopy
images, while free DOX was localized in the cell nucleus after
24 h (Fig. 21).107 Drug localization in intracellular organelles
has been proved for DOX loaded micelles by Laser scanning
confocal microscopy images. As shown in Fig. 21a,
MDAMB-231 cells exposed to free DOX show significant
accumulation of DOX in the nucleus after 24 h. In contrast,
cells exposed to DOX-loaded pH-sensitive micelles have a
punctate fluorescence, which is concentrated in the cytoplasm
after 24 h, as shown in Fig. 21b. These observations are impor-
tant for several reasons. First, the absence of DOX fluorescence
in the nucleus suggests that the micelles are stable in the pres-
ence of cells and serum-containing cell medium, as the rapid
destabilization of the micelles in the extracellular environment
and subsequent release of DOX outside the cell would be
expected to result in an image similar to that observed for free
DOX. In addition, the fluorescence in the cytoplasm suggests
that the DOX-loaded micelles are indeed taken up by cells, and
its punctate nature is consistent with the localization of the
drug in subcellular organelles.107 The increased stability of the
pH-sensitive system at pH 7.4, and controlled release of thera-
peutics in mildly acidic physiological environments make the
DOX-loaded PEO-block-G3 polyester (bis-MPA) dendrimer,
bearing cyclic acetals of 2,4,6-trimethoxybenzaldehyde, prom-
ising for anticancer drug delivery. The somewhat lower toxicity
of the micelle system was observed in comparison with free
DOX. However, the potential for the selective accumulation of
the micelle system in tumor tissue by the enhanced per-
meation and retention eﬀect may enhance its overall thera-
peutic eﬃcacy in vivo relative to free DOX.107
Cellular uptake evaluations on Raji lymphoma cells indi-
cated that cells treated with DOX–PEG5k–CA8 (Compound 7)
and DOX–PEG2k–CA4 micelles showed MFI (median fluo-
rescence intensity) 1.8-fold and 1.9-fold higher than free DOX,
respectively, proving eﬃcient internalizing of drug loaded
micelles in the mentioned cells.108 Similar in vitro cytotoxici-
ties have been found for drug loaded micelles against T- and
B-lymphoma cells as the free drug, exhibiting IC50 values of
20–50 ng ml−1 DOX. The higher value of the maximum tole-
rated dose (MTD) found for DOX–PEG2k–CA4 micelles (15 mg
kg−1) compared to free DOX (10 mg kg−1) in non-tumor
bearing BLAB/c mice has been attributed to the prolonged cir-
culation time and the controlled drug release property.108 In
the case of DOX-loaded PAMAM-b-PDMAEMA-b-PNIPAM block
copolymer-modified magnetic iron oxide nanoparticles (Com-
pound 8),109 in vitro cytotoxicity studies revealed higher inhi-
bition on Hela cells for free DOX (IC50 = 0.66 mg mL
−1), in
comparison with the loaded DOX in the modified nanoparti-
cles (IC50 = 1.49 mg mL
−1) at the same concentrations of DOX.
This result has been explained by the slow release of the drug
from the drug-loaded nanoparticles. At the same time, the
result confirmed that the DOX-loaded nanoparticles were ben-
eficial for decreasing the side eﬀects of DOX on cells.109
In vitro cytotoxicity of blank Fe3O4-dendritic–linear-brush-like
copolymer PAMAM-b-PDMAEMA-b-PPEGMA nanoparticles on
NIH 3T3 cells demonstrated cell viability of almost 100%.110
Also an in vitro hemolysis assay with rabbit erythrocytes con-
firmed the high biocompatibility of the Fe3O4-modified nano-
particles. In vitro cytotoxicity investigations on HeLa cells
showed IC50 values of 2.72 µg mL
−1 and ∼0.72 µg mL−1 for
DOX loaded in the modified nanoparticles (Compound 9) and
free DOX, respectively. This result demonstrated that dendri-
tic–linear-brush-like structures retard the toxic eﬀect of DOX
on the cells due to the slow release of the drug from the drug-
loaded nanoparticles, indicating that the modified nanoparti-
cles can delay drug release, in which a more compact brush
structure would possibly result in a lower diﬀusion rate of
drug molecules.110 This system oﬀers the preparation of water
soluble and biocompatible modified Fe3O4 nanoparticles for
the physical encapsulation of DOX. pH-sensitive and delayed
drug release was reported, which can be beneficial to further
facilitate potential biomedical applications of magnetic nano-
particles. Of course, biodistribution investigations and in vivo
studies are necessary.110 It has been shown that all drug
loaded PEG–Gn–PCL systems (Compound 10) delivered an
eﬀective dose of DOX to the breast cancer cells, comparable to
that of the free drug.102 Determined by in vitro cytotoxicity
Fig. 21 Laser scanning confocal microscopy images of (a) DOX and (b)
DOX-loaded pH-sensitive micelles (PEO-block-G3 polyester dendrimer
of 2,2-bis(hydroxymethyl)propanoic acid units bearing cyclic acetals of
2,4,6-trimethoxybenzaldehyde) incubated with MDAMB-231 cells for
24 h. Reprinted with permission from ref. 107. Copyright (2005) Ameri-
can Chemical Society.
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studies, cell viability was decreased to 60–80% for
MDA-MB-231 cells at 1 µg mL−1 concentration of loaded DOX,
while at lower concentrations than 1 µg mL−1 the cell viability
was 60% for MDA-MB-468 cells. The higher toxicity of free and
loaded DOX on MDA-MB-468 cells contributes to the greater
sensitivity of MDA-MB-468 cells to DOX. As proved by confocal
imaging, the intensity of DOX fluorescence, released from
DOX-loaded micelles, increased with time, and the fluo-
rescence became more concentrated in the cell nuclei at the
later time-point (Fig. 22).
According to flow cytometry investigations, in spite of the
lower cellular uptake of DOX from the carrier-loaded DOX, the
level of apoptosis of cells was comparable for free DOX and
carrier-loaded DOX, confirming the PEG–Gn–PCL system as a
promising anticancer drug carrier.102 Biocompatibility of
empty micelles, good drug loading eﬃcacy and eﬃcient killing
of the breast cancer cells, in spite of the lower cellular uptake,
are significant advantages of the DOX loaded PEG–Gn–PCL
system. However, to reduce the release rates and potentially
the observed aggregation of the drug-loaded micelles, a longer
PEG component is most likely necessary. Pharmacokinetics
and other in vivo investigations are also necessary.102
In vitro cytotoxicity assays on the murine colon adeno-
carcinoma tumor C26 line demonstrated higher anticancer
eﬀects for DOX/PG–PEG–PG/MWCNTs (Compound 11), in
comparison with free DOX in equal concentrations. With
respect to this point that equal concentrations of free DOX and
the DOX/PG–PEG–PG/MWCNT drug delivery system mean a
much lower concentration of DOX in the latter case, the toxi-
city of DOX molecules loaded inside LLNs against cancer cells
is much higher than those shown in Fig. 23.125 Hydrophilic
dendritic polymers not only raise the functionality, biocompat-
ibility and water solubility of CNTs but also change their con-
formations from a linear to a packed state. Changes in the
conformation of the CNTs upon noncovalent interactions with
PG–PEG–PG ABA type linear–dendritic copolymer led to lipo-
some-like nanocapsules (LLNs). Since one of the proposed
reasons for the carcinogenicity of carbon nanotubes is their
length and rigid structure, flexible liposome-like nanocapsules
prepared by this strategy could be safer and far from the asbes-
tos-like physicochemical properties of CNTs and therefore
their potential health hazards. Avoiding these health hazards,
it is possible to develop CNTs for biomedical applications.125
By in vitro cytotoxicity tests conducted on mouse tissue con-
nective fibroblast adhesive cell line (L929), it was found that in
low concentrations the toxicity of DOX-loaded Fe3O4-MWCNTs/
PAMAM–PEG–PAMAM hybrid nanomaterials (Compound 12)
was much higher than other systems and even free DOX, indi-
cating the critical role of the carbon nanotube in transferring
hybrid nanomaterial drug delivery systems, and therefore
loaded DOX, from the cell membrane.32 Since PEG improves
the processability, water solubility and long blood circulation
of CNTs through non-covalent interactions, supramolecular
interactions between linear–dendritic PAMAM–PEG–PAMAM
copolymers and CNTs lead to water soluble and high func-
tional hybrid nanomaterials. Additionally, high loading
capacity, higher toxicity compared to free DOX, and good
superparamagnetic behavior make DOX/γ-Fe3O4-MWCNTs/
PAMAM–PEG–PAMAM a promising material for anticancer
drug delivery.32
By in vitro cytotoxicity assays in the breast cancer cells
(MDA-MB-231), the PEG-block-bis-MPA polyesters (G4)-(Bz)8
have been found to be nontoxic.94 Also a reduced cell viability
of 55% has been determined for DOX–PEG-(G4)-(Bz)8 (Com-
pound 13) containing 10 µg ml−1 DOX, in comparison with
73% cell viability obtained at the same concentration of free
DOX, showing that DOX-loaded micelles delivered the thera-
peutic eﬀect with high eﬃcacy.129 In summary, DOX encapsu-
lated PEG-block-bis-MPA polyesters (G4)-(Bz)8 showed some
advantages, such as nontoxicity of the linear–dendritic carrier
and the higher cytotoxic eﬀect against MDA-MB-231 cancer
Fig. 22 Confocal microscopy of DOX in MDA-MB-468 cells. Cells were
cultured in the medium with DOX-PEG5k-G1-PCL60 (containing 2 µg
mL−1 DOX) for 4 h (A) and 24 h (B). Both images were captured with the
same parameters on confocal microscopy and adjusted to the same
contrast level and brightness. Reprinted with permission from ref. 102.
Copyright (2011) Wiley Periodicals, Inc. Fig. 23 The MTT assay results for opened MWCNT, PG–PEG–PG
linear–dendritic copolymer, DOX/PG–PEG–PG/MWCNT drug delivery
system and free DOX incubated with murine colon adenocarcinoma
tumor C26 line. Reprinted with permission from ref. 125. Copyright
(2012) The Royal Society of Chemistry.
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cells in comparison with free DOX. However, higher molecular
weights of PEG are necessary to provide suﬃcient stealth or
steric repulsion during DOX loading and to avoid aggregation.
Additionally, strategies for achieving better controlled release
kinetics should be noticed. Pharmacokinetics studies and
in vivo tests can help this system develop for cancer therapy.129
By flow cytometry profiles it has been proved that the DOX-
loaded PEO5K–PAMAM (D3)–diazonaphthoquinone (DNQ)
micelles (Compound 14) could quickly enter into HeLa cells in
a time-independent manner compared with free DOX
(Fig. 24).132 This phenomenon has been attributed to the
nanomedicines of <200 nm internalization by HeLa cells in an
endocytosis process, compared with a diﬀusion process for the
cellular uptake of free DOX.135 In vitro cytotoxicity studies eval-
uated in HeLa cells at 6 μg mL−1 DOX dosage showed the cell
viability of ∼65% and ∼18% for the DOX-loaded PEO5K–
D3DNQ micelles and free DOX, respectively. This lower cytotox-
icity of DOX-loaded micelles corresponds to their sustained
drug-release behaviour. Interestingly, the cell viability for the
DOX-loaded micelles decreased to ∼35% after 30 min of
808 nm irradiation, exhibiting a NIR-triggered cytotoxicity.132
Collectively, DOX-loaded PEO5K–PAMAM (D3)–diazonaphtho-
quinone (DNQ) micelles demonstrated some interesting
advantages, including the stability of drug-free micelles in PBS
at 37 °C and pH = 7.4, tuned release of DOX by NIR light
irradiation, quick entrance into HeLa cells compared to free
DOX, DOX release inside the cells, and then killing the cells in
a NIR-triggered manner. Disrupting the micelles by 808 nm
NIR irradiation may be a challenge for this system, however
biodistribution studies and in vivo tests can develop this prom-
ising anticancer system.132
5.1.3. In vivo evaluations. Biodistribution studies showed
2.0-fold and 2.2-fold higher drug uptake for DOX–PEG5k–CA8
and DOX–PEG2k–CA4 micelles compared to that for free DOX
in the tumor tissue of treated mice.108 This enhanced accumu-
lation corresponded to the prolonged circulation and the EPR
eﬀect in linear–dendritic micelle formulations (Compound 7).
Compared to free DOX, significantly reduced drug distribution
in the heart has been achieved by both DOX–PEG–CA formu-
lations. However, relatively higher uptake in the liver and
spleen has been exhibited for DOX-micellar systems caused by
nonspecific elimination of micellar NPs via the reticulo-
endothelial system (RES), such as macrophage in the liver and
spleen. Better inhibition of tumor growth was shown for DOX–
PEG2k–CA4 micelles because of their longer retention time and
slower drug release rate. By day 28 post-injection, the relative
tumor volume (RTV) of 7.7 and 6.8 was achieved for Raji lym-
phoma bearing mice treated with DOX–PEG5k–CA8 and DOX–
PEG2k–CA4, respectively. This value was 9.9 for free DOX
treated mice.108 Besides stability under physiological con-
ditions, DOX encapsulated PEGmk–CAn micelles oﬀered some
significant advantages in comparison to free DOX, such as
higher in vitro cellular uptake, higher maximum tolerated
dose, increased retention time in the blood, higher uptake in
tumor tissue in vivo, higher antitumor eﬃcacy in vivo, and
reduced drug distribution in the heart. These all make PEGmk–
CAn micelles attractive for cancer therapy (Table 3).
108
5.2. Doxorubicin-conjugated linear–dendritic block
copolymers
5.2.1. Physicochemical properties. Padilla De Jesús
et al.136 have designed a soluble carrier for DOX consisting of
a 3-arm poly(ethylene oxide) (PEO) and three [G-2] dendritic
polyester with 2,2-bis(hydroxymethyl)propanoic acid monomer
units (Compound 15), providing the multivalency necessary
for drug attachment (Fig. 25). DOX has been covalently linked
to the linear–dendritic structure via an acid-labile hydrazone,
which can remain stable under physiological conditions, and
can be cleaved in the vicinity of a tumor prior to being interna-
lized by the cancer cell because of the more acidic environ-
ment around the tumor tissue.136
Drug release studies indicated that a 100% release would be
achieved after 10 min, 3 h, 26.5 h, and 10 days for pH 2.5, 4.5,
5.5, and 6.5, respectively. This confirms the suitability of the
hydrazone linkage for a pH-dependent release that is compati-
ble with conditions found in tumors.136
Gillies and Fréchet also reported interesting polyester den-
drimer–PEO bow-tie hybrids consisting of 2,2-bis(hydroxy-
methyl) propionic acid based polyester dendrimers and PEO
in which PEO was linked to the dendritic scaﬀold via carba-
mate bonds.137,138
Later, the [G-3]-(PEO5k)8-[G-4]-(OH)16 bow-tie structure
(molecular mass ∼45 kDa) was utilized to provide the dendri-
mer–DOX conjugates by coupling hydrazide linkers to the
hydroxyl groups of the bow tie (Compound 16), followed by
hydrazone formation with DOX hydrochloride and subsequent
chromatographic separation from free DOX. DOX loading was
consistently found to be 8–10 wt% for diﬀerent batches.139,140
Notably, the bow-tie DOX conjugate was readily dissolved in
water at DOX concentrations as high as 6 mg ml−1 (∼60 mg
ml−1 polymer), indicating that the PEO arms of the bow-tie
dendrimer can shield the hydrophobic drug moieties at the
core of the molecule, perhaps in a structure similar to that of a
unimolecular micelle. A volume average hydrodynamic dia-
meter of 8 nm for the conjugate was determined using
dynamic light scattering, indicating that intermolecular
Fig. 24 Flow cytometry histogram proﬁles of HeLa cells incubated with
free DOX (A) and DOX-loaded micelles of PEO5K–PAMAM (D3) DNQ (B)
for diﬀerent time intervals. Reprinted with permission from ref. 132.
Copyright (2013) The Royal Society of Chemistry.
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aggregation did not occur.139 The release of the drug from the
DOX-conjugated bow-tie polymer at pH 5.0 and 7.4 buﬀers at
37 °C was monitored chromatographically. At pH 5, the drug
was released from the dendrimer rapidly, and the concen-
tration of free doxorubicin in solution increased steadily with
t1/2 = 6 ± 1 h, reaching 100% release within 48 h. Only a small
amount (<10%) of the same compound was released after 48 h
at pH 7.4 (Fig. 26).139,140
Huang et al.141 have reported the liver-targeting potential of
polymeric prodrug of doxorubicin bearing Galactose conjugated
linear dendritic block copolymers. Galactose as the targeting
ligand has been conjugated to linear PEG, and DOX has been
coupled to the PAMAM dendritic section via an acid-labile hydra-
zone linker to produce the Gal-PEG-b-PAMAM-DOXn drug deliv-
ery system (Compound 17) (Fig. 27). It has been demonstrated
that the galactosylated drug carrier could reach hepatocytes via
receptor-mediated active targeting, due to the high aﬃnity of
asialo-glycoprotein (ASGP) receptor to galactosyl residues.142
Determined by 1HNMR, the molar ratio of DOX to copoly-
mer was 5.5 : 1, which was lower than the theoretical value
(8 : 1), because of the steric hindrance that leads to the lower
drug loading.
Table 3 Doxorubicin-encapsulated linear–dendritic block copolymers
Carrier name Size (nm) In vitro activity In vivo activity Advantages Ref.
PEO–Poly(bis-MPA)–2,4,6-
trimethoxybenzaldehyde
35 nm Lower cytotoxicity on
MDA-MB-231 breast cancer
cells for DOX-loaded carrier
(IC50 = 3 µg mL
−1) compared to
free DOX (IC50 = 0.8 µg mL
−1)
nb Stability at pH 7.4, controlled
release of therapeutics in mildly
acidic physiological
environments, potential for the
selective accumulation of the





PEG5k–CA8 12–17 Similar in vitro cytotoxicities
(IC50 = 20–50 ng ml
−1) of drug
loaded micelles and free drug








conditions, higher in vitro cellular
uptake, higher maximum
tolerated dose, increased
retention time in the blood,
higher uptake in tumor tissue in






32 Lower cytotoxicity (IC50 =
1.49 mg mL−1) on Hela cells
compared to free DOX
(IC50 = 0.66 mg mL
−1)
nb Stabilized magnetic iron oxide
nanoparticles, thermosensitive
release mode, decrease the side




30 Less cytotoxicity on Hela cells
(IC50 of 2.72 µg mL
−1)
compared to free DOX (IC50 of
0.72 µg mL−1)
nb Water soluble and biocompatible
modified Fe3O4 nanoparticles as
carrier, pH-sensitive and delayed
drug release
110
PEG–G2 (bis-MPA)–PCL 865 Greater sensitivity of
MDA-MB-468 cells to DOX
released from micelles,
comparable level of apoptosis
of cells for free DOX and
carrier-loaded DOX
nb Biocompatibility of carrier
micelles, good drug loading
eﬃcacy and eﬃcient killing of the
breast cancer
102
PG–PEG–PG/MWCNTs 350 Higher anticancer eﬀects in




and water solubility of CNTs,
higher anticancer eﬀects




207 Higher cytotoxicity than free
DOX on mouse tissue
connective fibroblast adhesive
cell line (L929)
nb Water solubility and high
functionality of hybrid
nanomaterials. high loading
capacity, higher toxicity compared
to free DOX, and good
superparamagnetic behavior
32
PEG-poly(bis-MPA)-(Bz)8 300 Higher cytotoxicity eﬀects on
MDA-MB-231 breast cancer
cells compared to free DOX
nb Nontoxicity of linear–dendritic
carrier and higher cytotoxic eﬀect
in comparison with free DOX
in vitro
129
PEO–PAMAM–DNQ 160 (cac =
0.0206 mg mL−1)
Lower cytotoxicity of DOX-
loaded micelles in comparison
with free drug in HeLa cells
nb Stability in physiological
conditions, tuned release of DOX
by NIR light irradiation, quick
entrance into HeLa cells
compared to free DOX, DOX
releasing inside the cells
132
a A small fraction of aggregates. b n: not reported.
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The acid-sensitive degradation of the hydrazone linker
between DOX and the Gal-PEG-b-PAMAM carrier caused a pH-
triggered drug release profile. It has been determined that 14
and 32% of DOX was released at pH of 8.0 and 7.4, respect-
ively, in 30 h. On the other hand, at pH = 5.6, 97% of DOX
release was observed after 15 h. This indicates the stable circu-
lation of the polymeric drug in the bloodstream (pH = 7.4),
and triggered drug release in endosomes and lysosomes (pH =
5.6–6.5) of cancer cells.141
In a recent study, She et al. have demonstrated the use of
mPEGylated peptide Dendron–DOX conjugate (Compound 18)
as a pH-stimulated drug delivery system for breast tumor
therapy.143 In their study, the tail of the L-lysine dendron has
been functionalized with two alkynyl groups. Then, mPEG
(2 kDa) with an azido group at one end has been covalently
linked to the peptide dendron by CuI-catalyzed azide–alkyne
cycloaddition (CuAAC). DOX has been conjugated to the
dendron through a pH-sensitive hydrazone bond, resulting in
a compact nanoparticle, via self-assembly governed by
Dendron–DOX itself, as shown in Fig. 28.
UV-vis spectrophotometry indicated the presence of 2 DOX
molecules for each mPEGylated peptide Dendron-doxorubicin
(14 wt%). The mPEGylated peptide Dendron–DOX conjugate
Fig. 25 Polymer drug conjugate consisting of 3-arm PEO-polyester
dendrimer and doxorubicin using a hydrazone covalent bond as a linker
(Compound 15). Reprinted with permission from ref. 136. Copyright
(2002) American Chemical Society.
Fig. 26 [G-3]-(PEO5k)8-[G-4]-(OH)16-doxorubicin conjugates (Com-
pound 16). Reprinted with permission from ref. 140. Copyright (2006)
American Chemical Society.
Fig. 27 Gal-PEG-b-PAMAM-DOXn prodrug (Compound 17). Reprinted
with permission from ref. 141. Copyright (2010) Society of Chemical
Industry.
Fig. 28 Structures of mPEGylated peptide dendron, and the illustration
of the dendron-DOX conjugate based nanoparticle (Compound 18).
Reprinted with permission from ref. 143. Copyright (2012) Elsevier Ltd.
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aggregated to a nanosized particle in water (pH = 7.4), display-
ing average hydrodynamic sizes around 220 nm.143 Generally,
producing drive force segments is needed to introduce to the
PEGylation and functionalization of the dendron for self-
assembly.144 For this designed dendron, the self-assembly be-
havior was mediated by the mPEGylated peptide Dendron–
DOX itself. The primary driving force responsible for the self-
assembly behavior is the minimization of the interfacial
energy, governed by the balance between the hydrophilic inter-
action of the linear mPEG and the hydrophobic interaction of
the Dendron–DOX block.144 Secondly, the driving forces gov-
erning the self-assembly of the prepared mPEGylated peptide
Dendron–DOX, such as π–π stacking, dipole interactions, H-
bonding and the pre-organized branched architecture of the
dendritic block, should also be considered, since the DOX is
composed of multiple domains of diﬀerent chemical compo-
sitions, e.g., hydrophobic, aliphatic and aromatic.145 At pre-
determined time points, higher release amounts (80%) at pH 5,
in comparison with release amounts at pH 7.4 (20%), revealed
the pH-sensitive mode of drug release for mPEGylated peptide
Dendron-doxorubicin nanoparticles. This accelerated release
has been attributed to the cleavage of hydrazone linkers at
lower pH values.143
In another study She et al. have also used CuI-catalyzed
azide–alkyne cycloaddition (CuAAC) click chemistry to co-
valently attaching the L-lysine peptide dendron to heparin,
resulting in water-soluble dendronized heparin.146 Then, DOX
has been conjugated to the surface of the dendron through a
pH-sensitive hydrazone bond, resulting in a compact nanopar-
ticle via self-assembly in water (pH = 7.4), displaying average
hydrodynamic sizes around 90 nm and PDI of 0.140 (DOX
content 9 wt%) (Compound 19) (Fig. 29).
Self-assembly behavior was mediated by the dendronized
heparin-DOX conjugate itself. As mentioned before,146 the
primary driving force responsible for the self-assembly behav-
ior is the minimization of the interfacial energy governed by
the balance between the hydrophilic interaction of the linear
polymer and the hydrophobic interaction of the dendronized
heparin-DOX block. Secondly, the driving forces governing the
self-assembly of prepared dendronized heparin-DOX, such as
π–π stacking, dipole interactions, H-bonding and the preorga-
nized branched architecture should also be considered, since
the DOX is composed of multiple domains of diﬀerent chemi-
cal compositions, e.g., hydrophobic, aliphatic and aromatic.
Based on drug release profiles, showing 20% DOX release at
pH 7.4 after 56 h incubation, it was concluded that the dendro-
nized heparin-DOX system was stable in the circulation system
(pH 7.4). In contrast, cleavage of the acid-labile hydrazone
bonds of DOX-conjugated nanoparticles accelerated the
release of drug at pH 5.0 (>80%), indicating the ability of nano-
particles to release the DOX in the acidic endosomes and/or
lysosomes with pH ranging from 4.0–6.0.146
In a research work reported by Zhang et al.,147 a co-delivery
strategy for anti-cancer treatment has been employed, utilizing
10-hydroxycamptothecin (HCPT) encapsulated MPEG-b-
PAMAM-DOX amphiphilic linear–dendritic prodrug. In the
preparation route, MPEG-b-PAMAM G2.5 has been hydrazinoly-
sized to MPEG-b-PAMAM G3X by hydrazine hydrate. Then,
DOX as the hydrophobic part of the amphiphilic copolymer
has been conjugated to PAMAM via an acid-labile hydrazone
linkage by reacting with the keto groups of DOX. UV absor-
bance studies gave a DOX content of 52.9 wt% for MPEG2000-
b-PAMAM-DOX and 31.0 wt% for MPEG5000-b-PAMAM-DOX.
HCPT loading into DOX-conjugated nanoparticles has been
carried out by a solvent displacement method with pH
adjusted to 6.5, in which the hydrazone bond was stable while
HCPT could maintain its lactone form.148,149 HCPT content
has been determined to be 19.2 and 21.6 wt% for MPEG2000-
b-PAMAM-DOX and MPEG5000-b-PAMAM-DOX (Compound
20) nanoparticles, respectively. The nanoparticles were of
uniform size and spherical shape. The radii of nanoparticles
formed by MPEG2000-b-PAMAM-DOX and MPEG5000-b-
PAMAM-DOX were about 50 and 60 nm, respectively. As a
hydrophobic molecule, HCPT was wrapped in the core of the
nanoparticles, which were formed by the self-assembly of
MPEG-b-PAMAM-DOX prodrugs. The radii of the HCPT loaded
nanoparticles formed by MPEG2000-b-PAMAM-DOX and
MPEG5000-b-PAMAM-DOX were 88 nm and 122 nm, respect-
ively. The increase in size of the nanoparticles after HCPT
loading indicates the successful incorporation of HCPT in the
hydrophobic core.147 A pH-dependent release mode has been
demonstrated for both drugs released from HCPT loaded
MPEG-b-PAMAM-DOX. There has been no initial DOX burst
release from DOX-conjugated nanoparticles because of the
chemical combination of DOX to the copolymer. The release of
DOX molecules was negligible at pH 7.4, indicating the stabi-
lity of a hydrazone bond at this pH. Lowering the pH to 5.5
and 4.5 caused an increase in DOX release of about 30% and
60% in 48 h, respectively. Also faster release of HCPT has been
demonstrated in pH 4.5 compared to pH 5.5, attributed to the
faster cleavage of DOX and faster disassembly of the self-
assembled nanoparticles at lower pH (Fig. 30).147
Another pH-responsive prodrug formulation based on
linear–dendritic MPEG-b-PAMAM has been recently reported
by Zhang et al.78 Firstly, linear–dendritic MPEG-b-PAMAM was
Fig. 29 Illustration of a dendronized heparin-DOX conjugate based
nanoparticle (Compound 19). Reprinted with permission from ref. 146.
Copyright (2012) Elsevier Ltd.
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modified with lipoic acid (LA) and then doxorubicin was con-
jugated to the modified structure by an acid-labile hydrazone
bond, resulting in amphiphilic structures that could be self-
assembled to the nanosized micelles (Compound 21) (Fig. 31).
Due to the significant glutathione (GSH) concentration diﬀer-
ence between the extracellular milieu (2–20 mM) and the cyto-
plasm (2–10 mM), the reduction responsive cross-linked
micelles are attracting more and more attention. Therefore,
the obtained MPEG-b-PAMAM-LA/DOX micelles have been
cross-linked by disulfide bonding through introducing 10 mol%
DTT relative to the lipoyl units in borate buﬀer (pH 8.5).
With the MPEG segment as the hydrophilic moiety and LA and
DOX as the hydrophobic moieties, the amphiphilic prodrug
self-assembled into spherically shaped micelles. The particle
size of the cross-linked prodrug particles was ∼140 nm. The
stability of the cross-linked MPEG-b-PAMAM-LA/DOX NPs was
evaluated in 20 mM PB solution for diﬀerent time intervals.
After standing for 4 days, 8 days and 16 days, the particle size
of the NPs only slightly changed from the original 144 nm to
161 nm after 16 days of incubation, also suggesting the good
stability of the cross-linked NPs. The change in the particle
size in response to 10 mM GSH was monitored over time in
20 mM PB solution, to investigate whether cross-linked NPs
can be de-cross-linked in a reductive environment. It was
shown that the addition of GSH led to a dramatic increase and
wide distribution of the particle size, implying the cleavage of
disulfide bonds by reduced GSH. The DOX loading content of
cross-linked MPEG-b-PAMAM-LA/DOX micelles has been deter-
mined to be 25.6 wt%. The high drug loading content has
been ascribed to the multiple amine groups on the PAMAM
backbone.78
A pH-dependent release for DOX from core-cross-linked
MPEG-b-PAMAM-LA/DOX nanoparticles has been demon-
strated. At pH 7.4, only about 6% of the loaded DOX was
released in 72 h, while about 35% of DOX was released at pH
5.5. These results indicate that the hydrazone bond is stable at
the physiological pH of 7.4, but would be cleaved at the endo-
somal pH of 5.5. Also reduction-sensitive release behavior has
been found for cross-linked MPEG-b-PAMAM-LA/DOX. At the
same pH value, higher DOX release has been achieved with a
higher GSH concentration. This has been attributed to the
cleavage of the disulfide bonds by GSH, leading to de-cross-
linking of the nanoparticles and the rapid release of DOX.78
5.2.2. In vitro evaluations. Based on in vitro cytotoxicity of
the drug–polymer conjugate, evaluated on three cell lines
B16F10, MDA-MB-435, and MDA-MB-231, the free drug was
more potent than the DOX-conjugated 3-arm (PEO) star–three
[G2] polyester dendritic block with bis-MPA units (Compound
15); 6-fold in the B16F10 cells, 50-fold in the MDA-MB-231,
and 9-fold in the MDA-MB-435 cells. Cell uptake of the
polymer–drug conjugate (monitored via fluorescence confocal
microscopy) proved the cell uptake of the conjugate by endo-
cytosis, through fluorescence observation in the cytosol. On the
other hand, both the cytoplasm and the nuclei were highly
fluorescent after exposure to free doxorubicin.136
In spite of substantial intratumoral concentrations of
polymer and drug, attempts at chemotherapy utilizing the doxo-
rubicin functionalized 3-armed (PEO) star–three [G2] poly-
ester bis-MPA dendrimer in murine tumor models (B16F10)
were largely unsuccessful.140 This was attributed to hydrazone
carboxylate linkages, which were utilized in this system to
attach a doxorubicin topolymeric structure (Fig. 25). Lee
et al.140 investigated the hydrolysis kinetics of hydrazone car-
boxylate linked doxorubicin and proposed intramolecular
nucleophilic attack of the C-14 hydroxyl of doxorubicin on the
carbonyl group of the hydrazone carboxylate linker (Fig. 32).
Fig. 30 Illustration of MPEG-b-PAMAM block copolymer conjugated
with DOX and its self-assembled HCPT loaded nanoparticles for the pH-
responsive intracellular release (Compound 20). Reprinted with per-
mission from ref. 147. Copyright (2013) Wiley-VCH Verlag GmbH & Co.
KGaA, Weinheim.
Fig. 31 Synthesis pathway of MPEG-b-PAMAM-LA/DOX (Compound
21). Reprinted with permission from ref. 78. Copyright (2014) the Royal
Society of Chemistry.
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The proposed intramolecular cyclization reaction involving
the doxorubicin C-14 hydroxyl and the carboxylate-substituted
hydrazone rationalizes the seemingly anomalous hydrolysis
kinetics seen for hydrazone carboxylate linked doxorubicin,
and provides a possible explanation for the poor antitumor
activity exhibited by polymer–doxorubicin conjugates utilizing
this specific type of linkage.140
In vitro cytotoxicity studies of polyester dendrimer–PEO
bow-tie hybrids, with a range of MWs 20–100 KDa as well as
low and high degrees of branching, on MDA-MB-231 cancer
cells, showed no significant toxicity up to 10 mg mL−1, the
highest concentration evaluated, with cell viabilities exceeding
85% relative to controls at all concentrations.138 The cytotoxic
activity of DOX-conjugated bow-tie polyester dendrimer–PEO
(Compound 16) on C-26 cells was found to be considerably
less than that for the free DOX on an equimolar basis (IC50,
DOX = 0.08 ± 0.02 µg ml−1; IC50, hydrazone bow-tie DOX =
1.4 ± 0.2 µg ml−1). This result was attributed to the slower rate
of cellular uptake for the dendrimers when compared with the
free drug and to the gradual release of free drug from the poly-
mers, due to hydrolysis of the linkers and the polyester dendri-
mer backbone.139
By in vitro cytotoxicity studies against Bel-7402 cells, the cell
viability has been determined as 11%, 60% and 50% in cells
treated with free DOX, non-targeting PEG-b-PAMAM-DOXm,
and targeting Gal-PEG-b-PAMAM-DOXn (Compound 17),
respectively, at DOX concentration of 40 μg mL−1.141 Compared
to free DOX, decreased cytotoxicity of the polymeric prodrugs
has been attributed to their gradual drug release profiles. Also
higher cytotoxicity of galactose conjugated prodrug in com-
parison with the non-targeting one has been explained by the
receptor-mediated higher cell uptake of Gal-PEG-b-PAMAM-
DOXn. ASGP receptors in Bel-7402 and galactosyl residue in
the prodrug are responsible for the increased intracellular
drug concentration.141
Lower in vitro cytotoxicity, evaluated on mouse breast
cancer cell line (4T1), was seen for mPEGylated peptide
Dendron–DOX conjugate nanoparticles (Compound 18) (IC50 =
151 ng mL−1) compared with free DOX (IC50 = 25.9 ng
mL−1).143 This has been explained by the amphipathic pro-
perties of DOX and the higher ability of small molecules to
cross the cell membrane. Cell viability of 95% for non-drug
conjugated nanoparticles indicated that the mPEGylated
peptide dendron was nontoxic and DOX released from the
DOX-conjugated nanoparticle in the acidic environment of
endosomes was responsible for cytotoxicity.143
Dendronized heparin–DOX (Compound 19) showed IC50 of
300 ng mL−1 against the mouse breast cancer cell line (4T1),
approximately 11-fold of free DOX with IC50 of 27 ng mL
−1.146
This lower cytotoxicity of dendronized heparin–DOX was due
to the amphipathic properties of free DOX and its ability to
easily cross the cell membrane. More than 90% of 4T1 cells
have still been alive after the treatment with drug-free dendro-
nized heparin, showing non-cytotoxicity of the dendronized
heparin nanoparticle. So it is clear that the cytotoxicity of the
nanoparticle with the drug would not be due to the dendro-
nized heparin block, but the drug DOX, proving the release of
DOX from the nanoparticle in the acidic environment of
endosomes.146
Flow cytometric analysis demonstrated that HCPT loaded
MPEG-b-PAMAM-DOX nanoparticles (Compound 20) could be
eﬀectively taken up by MCF-7 cells.147 After 10 h incubation
with MCF-7 cells, about 80% HCPT has been internalized by
MCF-7 cells from both HCPT loaded MPEG-b-PAMAM-DOX
nanoparticles, much higher than the internalization content of
free HCPT, indicating that DOX conjugated nanoparticles
increased the solubility of free HCPT and delivered HCPT
eﬃciently to MCF-7 cells. Higher in vitro cytotoxicity has been
determined for HCPT loaded MPEG-b-PAMAM-DOX nanoparti-
cles compared to free DOX and free HCPT in MCF-7 and HepG2
cell lines. Moreover, the HCPT loaded MPEG-b-PAMAM-DOX
exhibited better cytotoxicities than the physical mixtures of
MPEG-b-PAMAM-DOX and HCPT.147 This confirmed that the
DOX conjugated prodrugs could eﬀectively encapsulate HCPT
and subsequently release it in the cell, leading to enhanced
drug activity and better in vitro antitumor eﬀect for the co-deliv-
ery system. Enhanced cell apoptosis has been demonstrated for
the co-delivery system. Evaluated by flow cytometry in MCF-7
cells, HCPT loaded MPEG2000-b-PAMAM-DOX and MPEG5000-
b-PAMAM-DOX caused 13.3 and 13.4% late apoptotic cells and
81.7 and 81.3% normal cells, respectively. Both HCPT loaded
nanoparticles resulted in more apoptotic cells than the blank
MPEG-b-PAMAM-DOX nanoparticles (4.7% late apoptotic cells
and 89.2% normal cells for MPEG2000-b-PAMAM-DOX, 4.9%
late apoptotic cells and 88.6% normal cells for MPEG5000-b-
PAMAM-DOX) and free HCPT (6.1% late apoptotic cells and
88.8% normal cells) with a concentration of 1 µg mL−1.147 The
advantages of co-delivery of two anticancer drugs (DOX and
HCPT), high drug loading content, pH-dependent drug release,
higher cellular uptake compared to free HCPT, and higher
in vitro cytotoxicity compared to free HCPT and free DOX, make
HCPT loaded MPEG-b-PAMAM-DOX nanoparticles attractive for
drug delivery. More investigations, especially pharmacokinetic
studies and in vivo antitumor eﬃcacy, can help this system
develop for cancer therapy applications.147
By comparison of the CLSM results in HeLa cells, after
3 and 16 h incubation with cross-linked MPEG-b-PAMAM-LA/
Fig. 32 Intramolecular cyclization in a hydrazone carboxylate linked
doxorubicin system. Reprinted with permission from ref. 140. Copyright
(2006) American Chemical Society.
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DOX micelles (Compound 21) (Fig. 33), it has been determined
that the eﬀective cellular uptake of the nanoparticles and
eﬃcient DOX release had taken place after a longer period of
incubation.78 In fact, after cellular uptake, the acidic environ-
ment and the relatively higher GSH concentration in both
endosomes and the cytoplasmic matrix triggered the cleavage
of the hydrazone bonds and disulfide bonds of cross-linked
MPEG-b-PAMAM-LA/DOX, causing the slow release of DOX.
Also the weaker DOX fluorescence observed for the cells
treated with cross-linked MPEG-b-PAMAM-LA/DOX nanoparti-
cles in comparison with that of free DOX has been explained
by slower internalization and the self-quenching eﬀect of DOX
in the nanoparticles.78
By in vitro cytotoxicity studies it has been found that cross-
linked nanoparticles have been more eﬀective after a longer
period of incubation. The IC50 value of the cross-linked nano-
particles decreased from 18.9 µg mL−1 to 2.5 µg mL−1 for HeLa
cells, with increasing incubation time from 24 to 72 h. The
decrease of IC50 has also been shown for A549 cells from more
than 20 µg mL−1 to 6.3 µg mL−1 under the same incubation
conditions. Enhanced inhibition of the cell proliferation has
been demonstrated for cross-linked nanoparticles incubated
with GSH pretreated HeLa and A549 cells. This higher cytotoxi-
city has been attributed to the cleavage of disulfide cross-
linking by GSH and faster release of DOX.78 Because of the
high drug loading content, pH and reduction-sensitive DOX
release behavior (regarding the acidic environment and the
relatively higher GSH concentration in both endosomes and
the cytoplasmic matrix), higher in vitro cytotoxic eﬀect with
the increase in incubation time, the core cross-linked MPEG-b-
PAMAM-LA/DOX NPs showed bright prospects for anti-cancer
therapy. However, investigations of in vivo eﬃcacy, tolerable
doses, and biodistribution studies are needed to complete the
cross-linked MPEG-b-PAMAM-LA/DOX system.78
5.2.3. In vivo evaluation. Biodistribution Studies of the
DOX-conjugated 3-arm (PEO) star–three [G2] polyester dendri-
tic blocks with bis-MPA units (Compound 15) performed on
CD-1 female mice demonstrated no significant accumulation
in any vital organ, including the liver, heart, and lungs
(Fig. 34).136 This is a preferred distribution pattern compared
with the free drug, which partitions into a variety of organs
such as the liver and heart. Also the polymer–DOX conjugate
exhibited a longer circulatory half-life (72 min), as compared
to the half-life of the free drug (8 min), demonstrating the
influence of the 3-arm PEO–polyester dendritic system in the
pharmacokinetics and the distribution of the drug.136
According to the reported results, it is concluded that DOX-
conjugated 3-arm (PEO) star–three [G2] polyester dendritic
block with bis-MPA units (Compound 16) shows advantages
including biocompatibility of the carrier, pH-dependent
release, which is compatible with conditions found in tumors,
no significant accumulation in vital organs, and a longer circu-
latory half-life than the free drug. But its lower cytotoxicity in
comparison with the free drug arises from hydrazone carboxy-
late linkages, which lead to the intramolecular cyclization reac-
tion and subsequent poor antitumor activity.136,140
According to biodistribution studies of bow-tie polyester
dendrimer–PEO138 on CD-1 female mice at a dose of approxi-
mately 40 mg kg−1, no specific organ accumulation was
observed for these bow-tie polymers, with a significant portion
of the dose (35–46%) found in the carcass after 48 h. Less than
4% of the dose was found in the urine for each of these poly-
mers, indicating that their eﬀective sizes are above the
threshold for renal filtration. After 48 h, 6–16% of the dose
was excreted in the feces. Therefore, the primary route for
elimination of these molecules was via intestinal excretion,
believed to be the primary route by which large molecules that
cannot be excreted through the kidney can escape the body.138
Biodistribution experiments of DOX-conjugated bow-tie
polyester dendrimer–PEO performed in BALB/c mice bearing
Fig. 33 Confocal laser scanning microscopy of HeLa cells (1.0 × 105
cells per well) after incubation with (A) free DOX, (B) cross-linked MPEG-
b-PAMAM-LA/DOXNPs (the cells were not pretreated) and (C) cross-
linked MPEG-b-PAMAM-LA/DOXNPs (the cells were pretreated with
10 mM GSH) for 3 h and 16 h at 37 °C (DOX equivalent concentration:
0.5 µg mL−1 for all formulations). The scale bars represent 20 µm. Rep-
rinted with permission from ref. 78. Copyright (2014) The Royal Society
of Chemistry.
Fig. 34 Biodistribution of 3-arm PEO–polyester dendrimer/DOX conju-
gate. Reprinted with permission from ref. 136. Copyright (2002) Ameri-
can Chemical Society.
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s.c. C-26 tumors showed an elimination half-life of 16 ± 1 h for
the hydrazone-linked bow-tie DOX conjugate.139 In previous
studies, a blood elimination half-life of 31 ± 2 h was observed
for a drug-free bow-tie PEO–polyester dendrimer.138 The long
circulation half-life of the conjugates contrasts with the short
half-life of the free drug, which is <10 min. The tumor concen-
trations of DOX measured 48 h after administration of either
DOX-conjugated bow-tie polyester dendrimer–PEO (20 mg kg−1
DOX) or free DOX (6 mg kg−1) were approximately nine times
higher for mice treated with DOX-conjugated bow-tie polyester
dendrimer–PEO by percentage injected dose per gram of
tumor. The enhanced tumor uptake of the dendrimer bound
drug is a reflection of its longer circulation half-life, which
exploits passive targeting by means of the EPR eﬀect.139
Animal serum analysis determined a significant increase in
the serum creatine kinase, lactic dehydrogenase, and serum
transaminase values in animals that received the 40 and 60 mg
kg−1 doses of DOX-conjugated bow-tie polyester dendrimer–
PEO, compared with animals that received saline or the 20 mg
kg−1 dose, indicating the presence of damage to muscle tissue
and to the liver at these dose levels. So it was concluded that
the maximum tolerated single dose is between 20 and 40 mg
kg−1 DOX equivalents or between ∼200 and 500 mg kg−1
DOX-conjugated bow-tie polyester dendrimer–PEO in healthy
BALB/c mice.139 To determine the optimal dosing schedule
for antitumor therapy, BALB/c mice bearing s.c. C-26 tumors
were administered a single dose of DOX-conjugated bow-tie
polyester dendrimer–PEO (10 mg kg−1 DOX) on various days
after tumor inoculation. Five diﬀerent groups of mice were
treated with a single i.v. injection of polymer on day 2, 4, 8,
12, or 16 after their tumors were implanted. The dosing sche-
dule experiment showed that mice treated on day 8
responded the most favorably to treatment, a result that was
statistically diﬀerent from the mice treated on days 4, 12, and
16. A dose–response experiment was performed by monitor-
ing the tumor growth and survival of BALB/c mice treated
with a single dose of DOX-conjugated bow-tie polyester den-
drimer–PEO, 8 days after implantation of a s.c. C-26 tumor.
Remarkably, at the highest dose administered (20 mg kg−1
DOX equivalents), complete tumor regression was observed,
resulting in 100% survival of mice in this treatment group
over the 60-day experiment. In contrast, none of the free DOX
(6 mg kg−1) administered mice were still alive on day 25. The
activity of the DOX-conjugated bow-tie polyester dendrimer–
PEO in vivo, despite its reduced in vitro toxicity relative to
free DOX, is convincing evidence of the dendrimer’s ability
to modulate the pharmacokinetic profiles of attached anti-
cancer drugs.139
Collectively, the DOX conjugated [G-3]-(PEO5k)8-[G-4]-(OH)16
bow-tie structure showed some significant advantages, for
example water solubility even at DOX concentrations of 6 mg
mL−1, pH-dependent release, no significant toxicity of the
carrier, long circulation half-life of the conjugates, and
enhanced tumor uptake. In spite of reduced in vitro toxicity,
the DOX-conjugated bow-tie polyester dendrimer–PEO showed
higher antitumor activity in vivo. These results introduce DOX-
conjugated bow-tie polyester dendrimer–PEO as a promising
anticancer system.138,139
The liver-targeting potential of galactose conjugated PEG-b-
PAMAM-DOXn prodrug (Compound 17) has been confirmed
using contrast-enhanced MRI carried out on Female ICR
mice.141 Comparison of signal enhancement in liver for Gal-
PEG-b-PAMAM-Gd and mPEG-b-PAMAM-Gd complexes showed
the maximum liver ENH of both agents after 6 h of injection.
Then, a rapid decrease of ENH has been observed for mPEG-b-
PAMAM-Gd. In contrast, Gal-PEG-b-PAMAM-Gd showed a
gradual decrease in ENH due to the high aﬃnity of the ASGP
receptor at the liver surface to galactosyl residues in Gal-PEG-b-
PAMAM-Gd, proving its active liver-targeting potential. In vivo
antitumor evaluations indicated inhibition of tumor growth
after Gal-PEG-b-PAMAM-DOXn administration (Fig. 35). Gal-
PEG-b-PAMAM-DOXn showed better in vivo antitumor eﬃcacy
than free DOX, suggesting its great potential as a polymeric
antitumor prodrug. In mice treated with free DOX, an increase
in tumor size was found after ten days. These data oﬀer Gal-
PEG-b-PAMAM-DOXn as a useful targeting anticancer agent.
141
Properties reported for Gal-PEG-b-PAMAM-DOXn, including
stability in pH 7.4, triggered drug release in pH 5.6–6.5 and
sensitivity of the drug vehicle to lower pH of tumor cells, recep-
tor mediated liver targeting, higher in vivo antitumor eﬃcacy
in spite of lower in vitro activity compared to the free drug
make this system interesting for anticancer investigations.
Additionally, biodistribution and pharmacokinetics studies
can develop this system.141
Determined by in vivo experiments, the tumor weights in
mice treated with mPEGylated L-lysine Dendron–DOX conju-
gate nanoparticle (Compound 18) were obviously lower com-
pared with the tumors from the free drug DOX treatment
group.143 The high antitumor activity of the DOX-conjugated
nanoparticle has been attributed to the neutral charged
surface, longer blood circulation, potential higher accumu-
lation in tumors via the EPR eﬀect and the accelerated release
of DOX from endosomes. Also a smaller shift in body weight
Fig. 35 In vivo antitumor eﬃcacy of (a) PBS, (b) DOX and (c) Gal-PEG-
b-PAMAM-DOXn (mean ± SD, n = 8). Reprinted with permission from
ref. 141. Copyright (2010) Society of Chemical Industry.
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shift has been observed for the group administrated DOX-con-
jugated nanoparticles compared to the free DOX treated ones,
indicating better drug tolerance. As shown in Fig. 36, histologi-
cally, for mice administrated free drug DOX, heart toxicity
induced by DOX was observed due to necrosis (grade 1), acute
infiltration of inflammatory cells at the epicardium and
cardiac myocyte under the epicardium. In contrast, the mice
administrated with drug-free peptide dendron and peptide
Dendron–DOX conjugate based nanoparticles were normal
and no visible diﬀerence was observed compared to the
control.143
According to in vivo experiments, higher antitumor activity
has been obtained for DOX-conjugated mPEGylated L-lysine
Dendron nanoparticles.143 Lower tumor weights have been
observed in mice administrated with DOX-conjugated nano-
particles in comparison with the tumors from the free drug
DOX treatment group. This result is caused by the neutral
charged surface, longer blood circulation, potential higher
accumulation in the tumor via the EPR eﬀect and the acceler-
ated release of DOX from endosomes.150 Also less body weight
loss has been observed for the group administrated DOX-con-
jugated nanoparticle compared to the free DOX treated ones,
indicating better drug tolerability. Histological analysis on
normal mice demonstrated the heart toxicity for mice admini-
strated free drug DOX.143 The toxicity has been attributed to
the necrosis (grade 1) with acute infiltration of inflammatory
cells at the epicardium and cardiac myocyte under the epicar-
dium (Fig. 36). In contrast, no toxicity has been observed in
mice administrated with drug-free nanoparticles and peptide
Dendron–DOX nanoparticles. The low molecular weight of the
mPEG-peptide dendron and its biodegradability, high accumu-
lation of DOX-conjugated nanoparticles in tumor tissue but
lower accumulation in normal tissue via EPR eﬀects, and the
Fig. 36 Histological analysis for diﬀerent organs of normal mice admi-
nistrated control (Saline), drug-free peptide dendron (Dendron), free
drug DOX (DOX) and mPEGylated peptide dendron-DOX conjugate
based nanoparticle (Nanoparticle) (heart: ×200, other tissues: ×100).
The analysis showed that the free drug DOX resulted in heart toxicity
due to the observed necrosis (grade 1) with inﬁltration of acute inﬂam-
matory cells in the epicardium and cardiac myocyte under the epicar-
dium (a3). In contrast, organs of mice administrated saline, drug-free
mPEGylated peptide dendron and mPEGylated peptide dendron–DOX
conjugate based nanoparticle did not exhibit signs of toxicity. Reprinted
with permission from ref. 143. Copyright (2012) Elsevier Ltd.
Fig. 37 In vivo tumor growth inhibition by nanoparticles. Comparison
of the tumor inhibition eﬀect of the dendronized heparin–DOX conju-
gate based nanoparticle with drug (Nanoparticle) versus free drug DOX
(DOX) and saline in the breast tumor model (n = 5). The nanoparticle
demonstrated signiﬁcant tumor inhibition (*p < 0.001, compared to
Saline; $p < 0.001, compared to the free drug DOX) (a). At the end of this
experiment, tumor tissues were collected from each sacriﬁced animal
after 25 days treatment, photographed (b) and weighed (*p < 0.01, com-
pared to saline; $p < 0.05, compared to the free drug DOX) (c). Reprinted
with permission from ref. 146. Copyright (2012) Elsevier Ltd.
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sensitivity of the drug vehicle to the lower pH of tumor cells
promote clearance from the organism and thereby enhance
the in vivo biocompatibility.143 The overall structural design of
mPEGylated L-lysine Dendron–DOX conjugate and its pro-
perties, such as nontoxicity of the vehicle, pH-sensitive drug
release, enhanced tumor inhibition in vivo in spite of lower
in vitro cytotoxicity in comparison with free DOX, better drug
tolerability, enhanced in vivo biocompatibility, and reduced side
eﬀects make this prodrug a safe and eﬃcient anticancer drug
delivery system.143 From in vivo studies on mice bearing the
4T1 breast tumor model, She et al. showed that the tumors
treated with dendronized heparin–DOX nanoparticle (Com-
pound 19) exhibited a significantly stronger response than the
tumors treated with saline only or free drug DOX.146 In particu-
lar, after 25 days of therapy, a statistically significant improve-
ment was obtained for mice treated with nanoparticles,
compared to the control and DOX treated groups, seen by the
much smaller tumor volume, as shown in the tumor growth
curves (Fig. 37a, p < 0.001). The tumor sizes from mice admini-
strated dendronized heparin–DOX conjugate based nanoparti-
cles were obviously smaller than those from the free drug
DOX treatment group and controls. (Fig. 37b), which was
proportional to the observed relative tumor volume results
(Fig. 37a). Simultaneously, the tumor weights in mice treated
with nanoparticles were noticeably lower compared with the
tumors from the free drug DOX treatment group (p < 0.05) and
control (p < 0.001) (Fig. 37c).146 The high antitumor activity of
the nanoparticle was attributed to the negatively charged
surface, longer blood circulation, potential higher accumu-
lation in the tumor via the EPR eﬀect and the accelerated
release of DOX from the endosomes.151 Regarding the advan-
tages of the non-toxicity of the carrier, pH-sensitive drug
release, and higher antitumor activity in vivo, dendronized
heparin–DOX may therefore be a potential nanoscale drug
delivery vehicle for breast cancer therapy. Certainly, pharmaco-
kinetics studies make this system more helpful for cancer
therapy purposes.146
Although these DOX-conjugated linear–dendritic polymer
systems demonstrated low in vitro cytotoxicities in comparison
with the free drug,136,141,143,146 the larger accumulation in
tumor tissue in vivo could counter balance the low in vitro toxi-
city. High molecular weight polymers preferentially accumu-
late in solid tumor tissue due to a combination of the leaky
character of tumor blood vessels formed during neo-angiogenesis
Table 4 Doxorubicin-conjugated linear–dendritic block copolymers




na Less cytotoxicity compared to




accumulation in any vital
organ, including the liver,
heart, and lungs evaluated
on CD-1 female mice
Biocompatibility of carrier,
pH-dependent release, no
significant accumulation in vital
organs, and longer circulatory
half-life than the free drug
136
8 Lower cytotoxic activity
(IC50 = 1.4 ± 0.2 µg ml
−1)
compared to free DOX
(IC50 = 0.08 ± 0.02 µg ml
−1)
on MDA-MB-231 cancer cells
Higher antitumor eﬀects
compared to free DOX on
BALB/c mice bearing s.c.
C-26 tumors
Water solubility even at DOX
concentrations of 6 mg mL−1,
pH-dependent release, no
significant toxicity of carrier, long
circulation half-life of conjugates,
and enhanced tumor uptake and





na Reduced cytotoxic activity
compared to free drug against
Bel-7402 cells
Better in vivo antitumor
eﬃcacy than free DOX on
female ICR mice
Stability in pH 7.4, triggered drug
release in acidic pH, receptor
mediated liver targeting, higher





220 Lower cytotoxicity (IC50 = 151 ng
mL−1) compared with free DOX
(IC50 = 25.9 ng mL
−1) on mouse
breast cancer cell line (4T1)
Higher antitumor activity in
comparison with free DOX
Nontoxicity of vehicle, pH-
sensitive drug release, enhanced





90 Lower cytotoxicity (IC50 of
300 ng mL−1) compared with
free DOX (IC50 of 27 ng mL
−1)
against mouse breast cancer cell
line (4T1)
Higher antitumor activity
on mice bearing 4T1 breast
tumor model compare to
free drug
Non-toxicity of carrier, pH-
sensitive drug release, and higher




60 Higher in vitro cytotoxicity for
nanoparticles compared to free
DOX and free HCPT in MCF-7
and HepG2 cell lines
na Co-delivery of two anticancer
drugs (DOX and HCPT), high drug
loading content, pH-dependent
drug release, higher cellular
uptake compared to free HCPT,






Being more eﬀective after a
longer period of incubation on
HeLa cells and A549 cells
na High drug loading content, pH
and reduction-sensitive DOX
release behavior, higher in vitro
cytotoxic eﬀect with the elongation
of the incubating time
78
a n: not reported.
Review Polymer Chemistry
















































and to limited lymphatic drainage. The combination of these
two factors is responsible for the enhanced permeability and
retention eﬀect (EPR) observed with tumor tissue, which leads
to a passive targeting of drugs to tumors. In addition, the
larger hydrodynamic volume of polymers contributes to the
increased plasma half-life of the drug–polymer conjugates,
increasing the probability of accumulation of the therapeutic
agent in the tumor tissue by means of the EPR eﬀect. Drugs
have also been conjugated to polymers to improve their water
solubility properties, to decrease their toxicity due to local
accumulation of the drug prior to reaching the target tissue,
and to protect them from possible enzymatic degradation or
hydrolysis. So these DOX-conjugated linear–dendritic systems
are promising because they allow slow elution of doxorubicin
into the tumor after administration, since the nanoparticle has
much longer blood circulation time and higher accumulation
in tumor tissue due to the EPR eﬀect (Table 4).136,141,143,146
6. Cisplatin
Cisplatin (cis-dichlorodiammine platinum(II)) (CDDP) is one of
the most potent anticancer agents available today and is
widely used in the treatment of many malignancies, including
testicular, ovarian, bladder, head and neck, small cell and
non-small cell lung cancers because of its potent activity in
cross-linking DNA upon entering the cells. It preferentially
binds to the N7 atoms of guanine bases in DNA double-helix
strands, thereby preventing the strands from uncoiling and
separating. This prohibits the division of the cells and ulti-
mately results in cellular apoptosis.152–156 However, its clinical
use is limited due to its significant toxic side eﬀects, such as
acute nephrotoxicity and chronic neurotoxicity. CDDP shows a
rapid distribution over the whole body and high glomerular
clearance within 15 min after intravenous injection. A total of
90% of the cisplatin is bound to plasma proteins in the blood
and, thus, does not enter the cells; leading to lower thera-
peutic eﬃcacy. Therefore, much eﬀort has been devoted
to developing a drug delivery system aimed at increasing
the blood circulation period and accumulation in solid
tumors.157–159
6.1. Cisplatin-conjugated linear–dendritic block copolymers
6.1.1. Physicochemical properties. Using linear–dendritic
polycitric acid–polyethylene glycol–polycitric acid (PCA–PEG–
PCA) copolymers (Mw ∼2000 Da), Haririan et al. prepared con-
jugates of PCA–PEG–PCA–CDDP (Compound 22) in an
aqueous medium.160 Drug loading of about 6 wt% platinum
was achieved for the conjugates. By in vitro platinum release
tests, it was found that the release rate in the acidic pH (5.4)
was slightly greater and faster than the neutral pH (7.4), attrib-
uted to the catalytic eﬀect of the acidic conditions on the ease
of displacement of water molecules with chloride or carboxy-
late ions inside the cisplatin cavity.160 It was observed that
when the conjugates were formed from the dendrimers, an
increase in the particle size was seen in the conjugates
(141 nm), as contrasted with the dendrimers (85 nm). This
phenomenon can result from the crosslinking of the dendri-
mers with cisplatin, which intercalates between two of the den-
drimer molecules.160
In our previous study, we used polycitric acid–polyethylene
glycol–polycitric acid (PCA–PEG–PCA) linear–dendritic copoly-
mers to solubilize and functionalize multi-walled carbon nano-
tubes (MWCNTs) by noncovalent interactions.161 We showed
that a potential anticancer drug cisplatin can be conjugated to
the carboxyl functional groups of the dendritic blocks of PCA–
PEG–PCA linear–dendritic copolymers and then the prodrugs
interacted with the MWCNTs noncovalently, leading to for-
mation of MWCNT/PCA–PEG–PCA–CDDP hybrid nanomater-
ial-based drug delivery systems (HNDDSs) (Compound 23).
Based on our previous investigations, the cavity of the
polymer-functionalized carbon nanotubes is able to host nano-
particles of up to 15 nm in diameter, due to their high solubi-
lity and opened cavity. Since the size of an individual PCA–
PEG–PCA linear–dendritic copolymer is less than 10 nm,162,163
they can transfer conjugated CDDP molecules to the cavity of
MWCNT/PCA–PEG–PCA hybrid nanomaterials (Fig. 37b). As
shown in the TEM images, the synthesized hybrid nanomater-
ials “transfer” CDDP molecules, not only by conjugation to the
linear–dendritic copolymers on their surface but also in their
cavity. Drug release studies at 37 °C and pH 7.4 showed a slow
release rate, with cumulative release percentage around 40%
after 168 h (Fig. 38).161
In another study, we reported the conjugation of CDDP
with PCA–PEG–PCA/CNT/γ-Fe2O3NP hybrid nanomaterials
(Compound 23).164 Deposition of γ-Fe2O3 nanoparticles onto
the surface of CNTs led to magnetic CNT/γ-Fe2O3NP, and then
non-covalent interactions between PCA–PEG–PCA and CNT/
γ-Fe2O3NP resulted in PCA–PEG–PCA/CNT/γ-Fe2O3NP hybrid
nanomaterials with improved water solubility, functionality,
and potential application to target anticancer drugs. According
to TGA analysis, the weight percent of PCA–PEG–PCA linear–
dendritic copolymers absorbed onto the surface of CNTs is
around 45%. While the molecular weight of CNTs is much
more than that of linear–dendritic copolymers, it can be found
that a large number of linear–dendritic copolymers are
attached onto the surface of a CNT.164 Based on TGA thermal
Fig. 38 TEM images of (a) MWCNT/PCA–PEG–PCA and (b) MWCNT/
PCA–PEG–PCA–CDDP. Reprinted with permission from ref. 161. Copy-
right (2011) The Royal Society of Chemistry.
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analysis, the weight percent of CDDP in the CDDP/PCA–PEG–
PCA/CNT/γ-Fe2O3NP drug delivery system is around 7%. DLS
experiments show that the average diameter of CNT/γ-Fe2O3NP
hybrid nanomaterials in water changes from 977 to 190 nm
upon interaction with PCA–PEG–PCA linear–dendritic copoly-
mers, confirming that the conformation of CNTs converts
from the linear to the globular form. This is of great impor-
tance, because the shape and size of nanomaterial- and
especially CNT-based drug delivery systems aﬀect their toxicity
significantly, such that the carcinogenicity of CNTs is some-
times ascribed to their length, and has been compared to
asbestos fibers. It should be kept in mind that another reason
for the decrease in size of CNT/γ-Fe2O3NP hybrid nanomater-
ials could be the separation of their bundles toward individual
objects, due to the noncovalent interactions with linear–den-
dritic copolymers. The CDDP/PCA–PEG–PCA/CNT/γ-Fe2O3NP
drug delivery system in water is 11 nm bigger than the PCA–
PEG–PCA/CNT/γ-Fe2O3NP hybrid nanomaterial, proving that
the interaction of the CDDP/PCA–PEG–PCA anticancer prodrug
with the surface of CNT/γ-Fe2O3NP is weaker than that of the
PCA–PEG–PCA linear–dendritic copolymer. This result con-
firms that CDDP molecules are conjugated with the carboxyl
functional groups of PCA blocks and limit interactions
between linear–dendritic copolymers and hydroxyl functional
groups of iron oxide nanoparticles anchored onto the surface
of CNTs.164 VSM curves showed that the saturation of magneti-
zation of PCA–PEG–PCA/CNT/γ-Fe2O3NP hybrid nanomaterials
was smaller than that of CNT/γ-Fe2O3NP, but both had similar
properties (Fig. 39). This proved that the magnetic properties
of CNT/γ-Fe2O3NP were not influenced by the self-assembly of
PCA–PEG–PCA linear–dendritic copolymers on their surfaces,
indicating that the PCA–PEG–PCA/CNT/γ-Fe2O3NP hybrid
nanomaterial can be used as a promising material in cancer
diagnosis and therapy.164
6.1.2. In vitro evaluations. In vitro cytotoxicity assay evalu-
ated in CT26 cells (24 h incubation) demonstrated an IC50 of
0.8252 µg mL−1 for PCA–PEG–PCA (G2)–CDDP conjugates
(Compound 22), which was 9 fold lower than that of free cis-
platin. IC50 determined for PCA–PEG–PCA(G2)–CDDP conju-
gates in HT1080 cell lines (48 h incubation) was 0.973 µg
mL−1, which was 8.4 fold lower than that determined for
free cisplatin.160 These significantly higher toxicities were
explained by two factors: (1) higher uptake of the conjugates as
contrasted with the free cisplatin, due to the citric acid content
of the conjugates, together with the greater demands of cancer
cells for such energy sources during the time of incubation. (2)
Increased liberation of the drug, attributed to lysosomal
enzymes existing inside the cell, which gradually break down
the bond between cisplatin and the dendrimers.160
Regarding the nontoxicity of PCA–PEG–PCA and the in vitro
results gained for the conjugates of cisplatin–PCA–PEG–PCA,
including greater and faster drug release rate in acidic pH, and
greater cytotoxicity compared to free cisplatin, it is hoped that
these conjugates would be able to maintain the observed
potency in vivo and retain the parent drug conjugated at the
surface of the dendrimers in physiological plasma conditions.
Future in vivo studies will be able to clarify the potentiality of
these entities in the cure of both sensitive and resistant can-
cerous cells.160
In vitro cytotoxicity studies on murine colon adeno-
carcinoma tumor C26 cancer cells demonstrated higher
cytoxicity for MWCNT/PCA–PEG–PCA–CDDP HNDDSs (Com-
pound 23) in comparison with the free drug.161 This was
attributed to the complementary roles of carbon nanotubes
and PCA–PEG–PCA linear–dendritic copolymers. MWCNTs
raise the rate of “transferring” of the linear–dendritic copoly-
mers from the cell membrane. On the other hand, PCA–PEG–
PCA linear–dendritic copolymers improve the water solubility
of the MWCNTs and, due to their citric acid backbone PCA–
PEG–PCA, can probably be used as the source of energy by the
cells that cause to insert MWCNTs in the cell metabolism.161 In
summary, the results from this study showed a slow rate of cis-
platin release at physiological conditions and a higher cytotoxi-
city for MWCNT/PCA–PEG–PCA–CDDP in comparison with the
free drug, which make this system useful for anticancer
drug delivery. More studies in pharmacokinetics and the anti-
tumor eﬀect in vivo are required for developing this system in
cancer therapy.161
In vitro cytotoxicity tests conducted on the mouse tissue
connective fibroblast adhesive cell line (L929) demonstrated
that a 100 µg ml−1 concentration of CDDP/PCA–PEG–PCA/
CNT/γ-Fe2O3NP (Compound 24) killed more than 95% of
cancer cells (Fig. 40).164 This high toxicity was explained by
fast transfer through the cell membrane caused by CNT, and
high water solubility and ability to insert into the cell meta-
bolism caused by PCA–PEG–PCA.164
Noncovalent interactions between carbon nanotubes and
linear–dendritic copolymers lead to hybrid nanomaterials
having a hybrid of properties such as fast transfer through the
cell membrane, high functionality, water solubility, biocompat-
ibility, and ability to target drugs to tumors (Fig. 41). Suﬃcient
in vitro cytotoxicity makes this system attractive for future
in vivo studies (Table 5).164
Fig. 39 Hysteresis loop by VSM of: (a) CNT/γ-Fe2O3NP and (b) PCA–
PEG–PCA/CNT/γ-Fe2O3NP. Reprinted with permission from ref. 164.
Copyright (2011) The Royal Society of Chemistry.
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Camptothecin (CPT), a natural plant alkaloid extracted from
Camptotheca acuminate, is a promising antitumor agent that
acts by stabilizing a topoisomerase I-induced single strand
break in the phosphodiester backbone of DNA, thereby pre-
venting religation. This causes the destruction of DNA strands
during DNA replication in the cell cycle, which leads to cell
death if the broken DNA is not repaired.165–167 The drug is a
pentacyclic indole alkaloid, with the terminal ring converting
readily between the lactone in acidic environments (pH <5) to
the carboxylate (pH >8) form. In order for CPT to be active, the
lactone form must dominate. The opening of the lactone ring
at physiological pH and above, which produces the less active
and highly toxic carboxylate form, prevents the clinical appli-
cation of CPT in cancer therapy. Moreover, poor solubility in
water and in physiologically acceptable organic solvents
restricts practical use of the active lactone form of CPT.168–170
Attempts to overcome these limitations have involved the con-
jugation of camptothecin to biocompatible polymers (prodrug
approach),171 and encapsulation into liposomes,172 polymeric
micelles,173 dendrimers,174 and nanoparticles.175
7.1. Camptothecin-conjugated linear–dendritic block
copolymers
7.1.1. Physicochemical properties. Camptothecin has been
conjugated to PEG-block-dendritic polylysine to tailor the
hydrophobicity of amphiphilic linear–dendritic PEG–poly-
lysine–CPT conjugates (Compound 25).79 By CPT content-
controlled self-assembly, nanostructures – nanospheres or
nanorods of diﬀerent diameters and lengths, have been
obtained. As shown in Fig. 42, CPT–PDP containing a disulfide
bond and an NHS active ester group has been reacted with
PEG-block-dendritic polylysine (PEG45–DPLL–G2) of diﬀerent
generations. The CPT contents of PEG–polylysine G0–CPT,
PEG–polylysine G1–DiCPT, PEG–polylysine G2–TetraCPT and
PEG–polylysine G3–OctaCPT were 13.4%, 21.4%, 30.6%, and
38.9% by weight, respectively.
Fig. 40 Percentage survival of C26 cancer cells, assessed by the MTT
assay, after exposure to free CDDP, opened MWCNT, PCA–PEG–PCA,
MWCNT/PCA–PEG–PCA and MWCNT/PCA–PEG–PCA–CDDP at 12.5,
25 and 50 µg mL−1(n = 3). P.C. is the positive control. Reprinted with
permission from ref. 161. Copyright (2011) The Royal Society of
Chemistry.
Fig. 41 The MTT assay results for opened MWCNT, CNT/γ-Fe2O3NP,
PCA–PEG–PCA, PCA–PEG–PCA/CNT, PCA–PEG–PCA/CNT/γ-Fe2O3NP
and CDDP/PCA–PEG–PCA/CNT/γ-Fe2O3NP hybrid nanomaterials. Rep-
rinted with permission from ref. 164. Copyright (2011) The Royal Society
of chemistry.
Table 5 Cisplatin-conjugated linear–dendritic block copolymers
Carrier name
Size





141 Significantly higher cytotoxicity in CT26 cells (IC50
of 0.8252 µg mL−1 for conjugates, 9 fold lower than
free cisplatin) and in HT1080 cell lines (IC50 of
0.973 µg mL−1 for conjugates, 8.4 fold lower than
free cisplatin)
na Nontoxicity of carrier, greater and faster drug
release rate in acidic pH, and greater





371 Higher cytotoxicity for HNDDSs in comparison with
the free drug on murine colon adenocarcinoma
tumor C26 cancer cells
na Slow rate of cisplatin release at physiological
conditions and higher cytotoxicity compared





200 Higher cytotoxicity against the mouse tissue
connective fibroblast adhesive cell line (L929)
na Fast transfer through the cell membrane, high
functionality, water solubility,
biocompatibility, suﬃcient in vitro cytotoxicity
164
a n: not reported.
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PEG–polylysine G0–CPT and PEG–polylysine G1–DiCPT
formed uniform ∼100 nm nanospheres. Interestingly, PEG45–
TetraCPT and PEG45–OctaCPT formed unusual nanorods. The
nanorods of PEG–polylysine G2–TetraCPT were about 60 nm in
diameter and 500 nm long, and those of PEG–polylysine G3–
OctaCPT were about 100 nm in diameter and about 1 mm
long. The stability of the nanostructures was studied in PBS at
37 °C by DLS. PEG45–DiCPT nanospheres and PEG45–Tetra-
CPT nanorods were stable for over five days and their sizes
did not change over time, whereas PEG45–OctaCPT nanorods
aggregated slightly. None of these nanostructures released any
CPT under these conditions. In vitro drug release studies
showed no CPT release from PEG–polylysine–CPT formulations
due to the conjugation of CPT molecules by disulfide bonds,
which can be cleaved intracellularly by GSH, indicating stabi-
lity of formulations at physiological conditions but quickly
releasing the drug CPT once in the cytosol. GSH-mediated
release was evidenced by the addition of DTT, a strong redu-
cing agent similar to GSH, which caused the immediate
release of CPT-thioester (CPT-SH).79
7.1.2. In vitro evaluations. MTT assay on MCF-7 cells
determined the IC50 value 0.138 µg mL
−1 for PEG45–polylysine
G1–DiCPT, 0.073 µg mL
−1 for PEG45–polylysine G2–TetraCPT
and 0.070 µg mL−1 for PEG45–polylysine G3–OctaCPT, which
are higher than that of free CPT (0.008 µg mL−1).79
7.1.3. In vivo evaluations. Pharmacokinetics in BALB/c
mice determined elimination half-life times (t1/2) of 5.82 h for
PEG–polylysine G2–TetraCPT, which was significantly greater
than those of PEG–polylysine G1–DiCPT (1.61 h) and PEG–
polylysine G3–OctaCPT (1.70 h).
79 The prolonged circulation
time of the PEG–polylysine G2–TetraCPT nanorods has been
attributed to their elongated shape, which might align or
tumble in the flow to reduce clearance by the liver or spleen.
Biodistribution studies after 4 h i.v. administration to BALB/c
mice demonstrated the presence of nanostructures in the
spleen. Also accumulation of some PEG–polylysine G1–DiCPT
in the liver (15.75 ± 3.85% ID per g tissue), and a significant
amount of PEG–polylysine G3–OctaCPT in the lung (64.89 ±
2.63%) was observed.79 PEG–polylysine G2–TetraCPT had lower
concentrations in the liver and spleen than PEG–polylysine
G1–DiCPT. After 24 h, PEG–polylysine G1–DiCPT almost dis-
appeared from all the organs. The level of PEG–polylysine
G3–OctaCPT in the lung was also greatly reduced and little
remained in the spleen (10.53 ± 1.31% ID per g of tissue) and
liver (3.55 ± 0.57% ID per g tissue). PEG–polylysine G2–Tetra-
CPT was still found in the spleen (22.05 ± 6.33% ID per g
tissue) and blood (3.59 ± 0.29% ID per g blood).79 Collectively,
high drug content, stability of formulations under physiologi-
cal conditions, and a reduction-sensitive drug release profile,
which leads to fast release in cytosol, made this system suit-
able for drug delivery. It was demonstrated that PEG–polylysine
G2–TetraCPT conjugate nanorods with proper lengths can
unite the two opposites in cancer-drug delivery: long blood cir-
culation versus fast cellular uptake and drug retention in circu-
lation versus intracellular drug release, ideal for eﬃcient
tumor-drug delivery (Fig. 43).79
8. Conclusion
In summary, linear–dendritic block copolymers show great
potential in anticancer drug delivery applications. The high
architectural control and the option to tailor the properties of
the linear–dendritic copolymers to the specific requirements
of cancer therapy, including prolonged circulation times,
increased drug solubility, reduced drug toxicity, selective deliv-
ery to tumors by active targeting with covalently bonded
tumor-targeting agents, or passive targeting, resulting from
the enhanced permeability and retention (EPR) eﬀect, make
these nanostructures promising carriers for a variety of anti-
cancer drugs. The reported data demonstrate that in most
Fig. 42 Schematic illustration of PEG-dendritic polylysine (G2)–camp-
tothecin conjugation reaction (Compound 25). Reprinted with per-
mission from ref. 79. Copyright (2013) Elsevier Ltd.
Fig. 43 The biodistribution at 4 h (A) or 24 h (B) post i.v. administration
of the PEG–xCPT nanostructures. Dose, 10 mg CPT-eq. kg−1, n = 4. -
Reprinted with permission from ref. 79. Copyright (2013) Elsevier Ltd.
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studies PEG has been utilized as a linear segment of linear–
dendritic anticancer carriers, because of its biocompatibility
and hydrophilic properties. The chemotherapeutic agents can
be loaded either as conjugated to the functional groups on the
dendritic blocks or encapsulated by the hydrophobic interior
of the dendritic segments of block copolymers. Several strat-
egies have been employed for the delivery of loaded chemo-
therapeutic agents by diﬀerent modes, such as pH-,
enzyme-, light-, and glutathione-dependent. In many cases,
slow drug release in physiological conditions, improved selecti-
vity and higher drug accumulation in tumor tissues, and
reduced drug toxicities were observed for drug loaded linear–
dendritic copolymers, indicating these nanostructures as
promising vehicles for anticancer agents. Although a large
number of studies, investigating the in vitro and in vivo antitu-
mor eﬃcacy of anticancer drugs loaded by linear–dendritic
copolymers are available, more research focusing on the bio-
distribution, pharmacokinetic studies, toxicity problems and
side eﬀects is needed. Clearly, more studies lead to better
knowledge in the design of linear–dendritic based anticancer
drug delivery systems, in order to achieve better targeting pro-
perties and higher antitumor eﬀects, and to avoid the uptake
in vital organs and side eﬀects that can be used to assist in the
optimization of clinical protocols (Table 6).
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